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PROJECT SUMMARY 
 
 Prescription drug abuse is an escalading problem in the U.S.  The mortality rate 
associated with prescription drug abuse is estimated at 46 deaths per day, with the 
majority of cases attributed specifically to prescription opioids (Centers for Disease 
Control and Prevention, 2014c; LJ Paulozzi, Jones, Mack, & Rudd, 2011; Substance 
Abuse and Mental Health Services Administration, 2014a).  In addition to the vast 
mortality rates, the morbidity associated with abuse has left a extensive impact on public 
health in the U.S.  While national prescription drug abuse rates have been extensively 
studied, the prevalence of prescription drug abuse is not well known in the State of 
Texas.  The main purpose of this study was to identify the current state of controlled 
substance prescription (CSP) utilization and aberrant CSP use in the State of Texas.  This 
was achieved through the objectives of this study, which included: 1) conducting 
descriptive statistics of patients utilizing CSPs and the frequencies of all classes of CSPs 
dispensed in Texas during 2013-2014; 2) identifying CSP utilization behaviors that are 
considered aberrant and highly associated with prescription drug abuse (e.g., use of 
multiple providers to obtain CSPs, overlapping CSPs, high daily dose of opioids); 3) 
utilizing patient-level, prescription utilization and county-level factors to identify the 
predictors of patient’s utilizing overlapping CSPs and also of having multiple provider 
episodes.  This study utilized the Texas Prescription Drug Monitoring Program Database 
(PDMP) for all analysis.  The PDMP database provided for a unique epidemiological 
approach to analyzing CSP use within a state, as all outpatient CSPs dispensed within the 
state are collected within this database.  The findings of this exploratory study will be 
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used to help build a foundation for identifying CSP prescribing practices and patient 
utilization of CSPs.  This study will also assist in informing both clinical care and policy 
decisions regarding CSP prescribing and identifying patients with aberrant CSP 
utilization behaviors. 
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Objectives 
 
Objective 1 
 
 The first objective aims to highlight aberrant CSP behavior which can be 
identifiable through PDMP data.  Three aberrant behaviors discussed in this paper 
include: receiving inappropriate and/or overlapping combinations of CSPs; utilizing 
multiple providers (i.e., doctor shopping) to obtain opioids and CSPs; and consuming a 
high daily morphine equivalents dose (MED).   
 
Objective 2 
 
 The second objective of this research was to identify the prevalence and factors 
associated with patients receiving potentially inappropriate overlapping CSPs in the State 
of Texas.  Logistic regression was used to identify the patient-level and prescription 
utilization factors associated with the use of potentially inappropriate combination of 
CSPs. 
 
Objective 3 
 
 The third objective of this study used the indicators of prescription drug abuse to 
identify the current state and burden of controlled substance prescription drug use and 
abuse in Texas.  Multilevel logistic modeling was employed to examine the prevalence 
and individual-level and regional-level factors associated with patients having an MPE in 
the State of Texas.   
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LITERATURE REVIEW 
 
 
1.1 EPIDEMIOLOGY OF CHRONIC PAIN 
 
 Chronic pain has been recognized as a significant public health problem and 
burden due to its prevalence, economic cost, biological and sociological impact (Institute 
of Medicine, 2011).  In the United States, it is believed that every year over 100 million 
Americans suffer from chronic pain conditions (Table 1.1), reaching epidemic 
proportions (The American Academy of Pain Medicine, 2012).  It is estimated that 
economic burden of chronic pain in the U.S. is around $635 billion annually, as a result 
of the associated health care costs, such as disability, lost wages, readmission and lost 
productivity (Institute of Medicine, 2011).  Pain currently affects more Americans than 
diabetes, heart disease and cancer combined (The American Academy of Pain Medicine, 
2012).  According to the American Chronic Pain Association, "chronic pain can be 
defined as ongoing or recurrent pain, lasting beyond the usual course of acute illness or 
injury, and which adversely affects the individual’s well-being" (American Chronic Pain 
Association, 2014).  The International Association for the Study of Pain (IASP) defines 
chronic pain as pain without apparent biological value that has persisted beyond the 
normal tissue healing time (usually taken to be three months).  However, chronic pain has 
proven to be a complex, subjective condition that a precise definition is unknown and 
varies across studies (Andersson, Ejlertsson, Leden, & Rosenberg, 1993; Peters et al., 
2013; Schopflocher, Taenzer, & Jovey, 2011; Smith et al., 2001). 
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Table 1.1. Incidence of Pain, as Compared to Major Medical Conditions 
Condition Number of Sufferers Source 
Chronic Pain 100 million Americans Institute of Medicine of The National Academies  
Diabetes 
25.8 million Americans 
(diagnosed and estimated 
undiagnosed) 
American Diabetes Association  
 
Coronary Heart 
Disease 
 
 
 
16.3 million Americans 
 
American Heart Association  
Stroke 7.0 million Americans American Heart Association 
Cancer 11.9 million Americans American Cancer Society  
Source: The American Academy of Pain Medicine, 2012 
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 Barriers to adequate pain treatment and care are one of the greatest contributors to 
the prevalence of chronic pain in the United States.  These barriers are the result of a 
multitude of factors, including limited physician education and training in pain 
management, provider attitudes, insurance coverage, cultural attitudes of patients, 
geographic barriers, and regulatory barriers (Institute of Medicine, 2011). 
 One consequence of the escalating rates of chronic pain is the increasing rates of 
prescription drug use, such as pain medications.  The effectiveness of treating chronic 
pain solely through the use of prescription medications, especially as a long-term 
treatment plan, is a highly debated topic (Institute of Medicine, 2011; Martell et al., 2007; 
Wu, Lang, Hasson, Linder, & Clark, 2010).  Research in this area including both clinical 
trials and observational studies have found limited evidence supporting the long-term use 
of prescription pain medications in treating chronic pain conditions. Many feel that the 
risks associated with using these medications outweigh the benefits (Chou, Ballantyne, 
Fanciullo, Fine, & Miaskowski, 2009; Kuijpers et al., 2011; Manchikanti et al., 2011; 
Trescot et al., 2008).  Therefore, managing chronic pain and providing appropriate 
medication therapy is a challenging facet for both primary care providers and specialists.  
Healthcare practitioners are conflicted in their efforts to appropriately treat non-cancer 
chronic pain and face a delicate balance between the under treatment of pain and the 
overprescribing of pain medications (Agency Medical Directors Group, 2010). 
 
 
1.2 CONTROLLED SUBSTANCE PRESCRIPTIONS 
  
 Controlled substance prescriptions are drugs that have some potential for abuse or 
dependence (AWARxE Prescription Drug Safety).  According to the U.S. Department of 
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Justice Drug Enforcement Administration Office of Diversion Control, drugs and other 
substances that are considered controlled substances under the Controlled Substances Act 
(CSA) are divided into five schedules.  Controlled substances are scheduled based on 
whether they have a currently accepted medical use for treatment in the United States, 
their potential for abuse, and their likelihood of causing dependence when abused (U.S. 
Department of Justice Drug Enforcement Administration Office of Diversion Control, 
2014).  Definitions of how controlled substances (Schedule I-V) are classified, along with 
common examples for each, are provided in Table 1.2. 
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Table 1.2. Definition of Controlled Substance Schedule 
Controlled 
Substance 
Schedule 
 
 
Definition 
 
 
Examples 
Schedule  
I 
This schedule has no 
currently accepted medical 
use in the United States, a 
lack of accepted safety for 
use under medical 
supervision, and a high 
potential for abuse 
Heroin, lysergic acid diethylamide 
(LSD), marijuana (cannabis), 3,4-
methylenedioxymethamphetamine 
("Ecstasy") 
Schedule  
II 
This schedule has a high 
potential for abuse which 
may lead to severe 
psychological or physical 
dependence 
Narcotics: combination products 
containing hydrocodone (Vicodin®), 
hydromorphone (Dilaudid®), methadone 
(Dolophine®), meperidine (Demerol®), 
oxycodone (OxyContin®, Percocet®), 
fentanyl (Sublimaze®, Duragesic®), 
morphine, opium, and codeine 
Stimulants: amphetamine 
(Dexedrine®, Adderall®), 
methylphenidate (Ritalin®) 
Schedule  
III 
This schedule has potential 
for abuse less than 
substances in Schedules I 
or II and abuse may lead to 
moderate or low physical 
dependence or high 
psychological dependence 
Narcotics: products containing not 
more than 90 milligrams of codeine 
per dosage unit (Tylenol with 
Codeine®), buprenorphine 
(Suboxone®) 
Non-narcotics: anabolic steroids, 
benzphetamine, phendimetrazine, 
ketamine 
Schedule  
IV 
This schedule has a low 
potential for abuse relative 
to substances in Schedule 
III 
alprazolam (Xanax®), carisoprodol 
(Soma®), clonazepam (Klonopin®), 
diazepam (Valium®), lorazepam 
(Ativan®) 
Schedule  
V 
This schedule has a low 
potential for abuse relative 
to substances listed in 
Schedule IV and consist 
primarily of preparations 
containing limited 
quantities of certain 
narcotics. 
Cough preparations containing not 
more than 200 milligrams of codeine 
per 100 milliliters or per 100 grams 
(Robitussin AC®, Phenergan with 
Codeine®) 
Source:  U.S. Department of Justice Drug Enforcement Administration Office of 
Diversion Control, 2014 
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1.3 PRESCRIPTION DRUG ABUSE: A NATIONAL EPIDEMIC 
 
 The nonmedical use of prescription drugs has been drastically rising in the United 
States, reaching what are now considered by the Centers for Disease Control and 
Prevention (CDC) as epidemic proportions (Centers for Disease Control and Prevention, 
2013b; S. E. McCabe, Cranford, & West, 2008).  Prescription drug abuse is a perilous 
public health problem that has resulted in an excess of deaths, emergency room visits and 
millions of healthcare dollars consumed. 
 Reported estimates of nonmedical use of prescription drugs are 20% of U.S. 
individuals aged 12 or older have reported abusing prescription drugs for nonmedical 
reasons at least once in their lifetime (Substance Abuse and Mental Health Services 
Administration, 2006).  The Substance Abuse and Mental Health Services Administration 
(SAMHSA) 2013 National Survey on Drug Use and Health (NSDUH) findings indicated 
that 15.7 million persons aged 12 or older reported using prescription-type drugs non-
medically within the past year (Substance Abuse and Mental Health Services 
Administration Center for Behavioral Health Statistics and Quality, 2013a).  This report 
from 2002 to 2012 indicates an over 75% increase in non-medical use of opioids (Jones, 
2012).  Additionally, 1.7% of the U.S. population (4.5 million) reported nonmedical use 
of pain relievers within the past month in 2013 (Figure 1.1) (Substance Abuse and Mental 
Health Services Administration, 2014a). 
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Figure 1.1.  Past Month Nonmedical Use of Drugs among Persons Aged 12 or Older: 
2002-2013 
 
 
Source: SAMHSA, 2013 
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 SAMHSA defines the nonmedical use of prescription drugs as use of drugs 
without a prescription or use that occurs simply for the experience or feeling the drug 
causes (Substance Abuse and Mental Health Services Administration Center for 
Behavioral Health Statistics and Quality, 2013a).  The terms abuse, dependence and 
misuse have separate definitions, however they are commonly used interchangeably in 
the literature and will be used interchangeably for the purpose of this research.   
 
1.3.1 MOST FREQUENTLY ABUSED CONTROLLED SUBSTANCES 
 Controlled substance medications can be effective when they are used 
appropriately, but can be addictive and potentially dangerous when abused.  There are 
three classes of prescription drugs that have been found to be the most frequently abused: 
opioid analgesics (e.g., morphine), central nervous system depressants (e.g., 
benzodiazepines) and central nervous system stimulants (e.g., methylphenidate) (U.S. 
Department of Health and Human Services National Institutes of Health, 2011). 
 
1.3.2 OPIOID ANALGESICS  
 Opioid analgesics (i.e., opioids) are prescription medications that reduce the 
intensity of pain signals reaching the brain by binding to opioid receptors in the brain and 
affecting the areas of the brain which control emotion, often diminishing the effects of a 
painful stimulus (U.S. Department of Health and Human Services National Institutes of 
Health, 2011).  Some examples of medications that fall into this category are codeine, 
morphine, hydrocodone, oxycodone, and fentanyl (National Institute on Drug Abuse, 
2011b).  There are several side affects and complications associated with both short-term 
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and long-term use, including constipation, nausea, dizziness, drowsiness (Furlan, 
Sandoval, Mailis-Gagnon, & Tunks, 2006), respiratory depression, and vomiting 
(Benyamin et al., 2008).  Opioid use for treating acute pain and terminal illness pain is 
generally well accepted in practice (Ballantyne & Shin, 2008; Noble et al., 2010).  
However, their use in the long-term treatment of chronic non-cancer pain is debated for 
many reasons, including their high risk for both physical and psychological dependence, 
as well as a lack of evidence for their efficacy in the long-term treatment of chronic non-
cancer pain (Benyamin et al., 2008; Manchikanti et al., 2011). 
 Research and associated statistics have also revealed devastating consequences 
related to overuse and abuse of opioids.  This includes increases in accidental overdose, 
abuse, addiction, diversion, and accidents involving injuries associated with opioid use 
(Agency for Healthcare Research and Quality, 2013; Substance Abuse and Mental Health 
Services Administration, 2011b, 2012a).  In 2009 opioids were found to be present in 
50% of cases seen in emergency departments related to nonmedical-use of 
pharmaceuticals (National Institute on Drug Abuse, 2011d).  According to the CDC, 
almost three out of four prescription drug overdoses are associated with prescription pain 
relievers, including opioids (Centers for Disease Control and Prevention, 2013b).  
Overdose deaths involving opioids exceed deaths involving all illicit drugs (e.g., heroin, 
cocaine) combined (Centers for Disease Control and Prevention, 2013c; LJ Paulozzi et 
al., 2011).  Based on 2014 estimates, the CDC reported that 46 individuals die each day 
from an overdose of opioid or narcotic pain relievers in the U.S. (Centers for Disease 
Control and Prevention, 2014c).  The CDC has also reported that in 2012, 72% of deaths 
related to pharmaceutical misuse were attributed to opioids (Centers for Disease Control 
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and Prevention, 2014d).  Peirce et al. (2012) reported that exposure to opioids was 
associated with a greater odds of drug-related death (odds ratio [OR]=3.39, 95% 
confidence interval [CI]=1.60-7.21) (Peirce, Smith, Abate, & Halverson, 2012).  Many 
opioid overdose deaths have been associated with chronic pain, with studies estimating 
that 50-80% of individuals dying from an opioid overdose had a history of chronic pain 
(E. Johnson et al., 2013; LJ Paulozzi et al., 2009).  
 
1.3.3 CENTRAL NERVOUS SYSTEM DEPRESSANTS 
 Central nervous system (CNS) depressants, also referred to as sedatives and 
tranquilizers, are substances that work by slowing brain activity by depressing the central 
nervous system, causing a drowsy or calming effect (National Institute on Drug Abuse, 
2011a).  CNS depressant medications are often prescribed for conditions such as anxiety, 
seizure disorders and sleep disorders and include medications such as benzodiazepines 
(e.g., Xanax®, Valium®), non-benzodiazepine sleep medications (e.g., Ambien®, 
Lunesta®), and barbiturates (e.g., phenobarbitals) (National Institute on Drug Abuse, 
2011a).  As with opioids, CNS depressants have a high potential for dependence and 
abuse (Hanson, Venturelli, & Fleckenstein, 2015).  In 2009 and 2010 over 42,000 
emergency room visits were attributed to overmedication of zolpidem (Ambien®), of 
which two-thirds of cases were females (Substance Abuse and Mental Health Services 
Administration Center for Behavioral Health Statistics and Quality, 2014). 
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1.3.4 CENTRAL NERVOUS SYSTEM STIMULANTS 
 Central nervous system stimulants (i.e., stimulants) increase alertness, attention, 
and energy by enhancing the effects of norepinephrine and dopamine chemicals in the 
brain (National Institute on Drug Abuse, 2011e).  Stimulants are often prescribed for 
attention deficit hyperactivity disorder (ADHD), narcolepsy and depression and include 
methylphenidate (e.g., Ritalin®) and amphetamines (e.g., Adderall®) (National Institute 
on Drug Abuse, 2011e).   The CDC currently estimates that 11% of children between the 
ages of 4-17 having been diagnosed with ADHD, and 6.1% of all children in this age 
category are taking a medication for ADHD (Centers for Disease Control and Prevention, 
2014a).  Nonmedical use and abuse of prescription stimulants, especially ADHD 
medications, is a rising problem across the country, especially among adolescents and 
college students (Children and Adults with Attention-Deficit/Hyperactivity Disorder 
(CHADD), 2015).  Prevalence rates of nonmedical use of stimulants among college 
students are between 4.1% and 10.8% (Arria, O'Grady, Caldeira, Vincent, & Wish, 2008; 
S. McCabe, Knight, Teter, & Wechsler, 2005; Teter, McCabe, LaGrange, Cranford, & 
Boyd, 2006). 
 
1.4 HEALTH OUTCOMES AND CONSEQUENCES ASSOCIATED WITH 
PRESCRIPTION DRUG ABUSE 
 
 The health consequences associated with misuse and abuse of prescription 
medications have been devastating to this country in recent years.  Drug overdose deaths 
were found to be the leading cause of injury death in the United States in 2012, 
outnumbering the number of deaths due to motor vehicle crashes (Figure 1.2) (Centers 
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for Disease Control and Prevention, 2014d).  The majority these cases were attributed 
specifically to opioids (LJ Paulozzi et al., 2011).   
Figure 1.2.   Rates of Motor Vehicle Traffic Crashes and Drug Overdose (1980-
2010) 
 
Source: U.S. Department of Health and Human Services, 2013.  
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 In addition to overwhelming mortality rates, the morbidity associated with abuse 
has increased to unprecedented levels, creating a drastic impact on public health in the 
U.S.  For every overdose death there is a multiplicity of relative negative health outcomes 
(Table 1.3).  Emergency department visits involving nonmedical use of pharmaceuticals 
increased 98.4% over a five-year period from 2004 to 2009, with oxycodone incidents 
increasing 242.2% and hydrocodone incidents increasing 124.5% (National Institute on 
Drug Abuse, 2011d).  An additional consequence not frequently well known are the 
adverse health consequences associated with long-term use of pain medication 
combination products containing acetaminophen (i.e., Vicodin®).  Acetaminophen 
overdose is the leading cause of acute liver failure in the U.S. and long-term use can lead 
to hepatotoxicity and even acute liver failure (Kurtovic, Riordan, & Williams, 2005; 
Larson et al., 2005; Michna, Duh, Korves, & Dahl, 2010). 
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Table 1.3. Health Outcomes Associated with Opioid Use 
For Every 1 Painkiller Death There Are… 
Abuse treatment admissionsa 9 
Emergency department visits for misuse abuseb 35 
People with abuse and/or dependencec 161 
Nonmedical usersc 461 
Source:  
a. Treatment admissions for primary use of opioids Treatment Exposure Data set;  
b. Emergency department (ED) visits are from Drug Abuse Warning Network;                 
c. Abuse/dependence and nonmedical use in the past month are from the National Survey 
on Drug Use and Health 
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 Individuals abusing prescription medications often regress to other forms of 
substance abuse (National Institute on Drug Abuse, 2014a). The use of prescription drugs 
for non-medical reasons is highly associated with other drug use behaviors, including 
cigarette smoking, heavy drinking, marijuana use and other illicit drug use (Boyd, 
McCabe, & Teter, 2006). 
 
 
1.4.1 ASSOCIATED HEROIN USE 
 
 Paralleling increasing opioids abuse rates, rates of heroin abuse, also an opiate, 
are on the rise.  Recent increases in the annual number of persons in the U.S. who used 
heroin for the first time have raised concerns that prior nonmedical use of prescription 
pain relievers may have led to heroin use in many individuals (Figure 1.3) (Substance 
Abuse and Mental Health Services Administration, 2012b).  A recent survey reported that 
the incidence rate of heroin was 19 times higher among those who reported prior 
nonmedical pain reliever use than among those who did not (Muhuri, Gfroerer, & Davies, 
2013).  Data from the National Survey on Drug Use and Health (NSDUH) has indicated 
that the number of individuals aged 12 or older with heroin dependence or abuse has 
more than doubled since 2002 (Muhuri et al., 2013).  A study by Martyres et al. (2004) 
also found that among young adults aged 14-24 who died from a heroin overdose, 80% 
had other prescription drugs in their system, of which most were either benzodiazepines 
or opioids (Martyres, Clode, & Burns, 2004). 
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FIGURE 1.3  Percentage of Heroin Initiates among Persons Aged 12 to 49, by Prior 
and Past Year Dependence/Abuse of Nonmedical Pain Relievers (NMPR): 2002-
2011 
 
 
Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey 
on Drug Use and Health, 2002-2004, 2005-2010 (2012). 
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1.4.2 ECONOMIC CONSEQUENCES  
 In addition to the devastating health-related consequences of prescription drug 
abuse, the economic burden due to the vast resource utilization and monetary costs of 
abuse are substantial.  It is estimated that abuse of opioids alone result in between $53-
$72 billion in medical costs each year (Birnbaum et al., 2011; Coalition Against 
Insurance Fraud, 2007; Hansen, Oster, Edelsberg, Woody, & Sullivan, 2011).  The 
economic figures associated with abuse account for medical and drug abuse treatment 
costs, lost productivity, medical complications and criminal justice costs (Birnbaum et 
al., 2011; Hansen et al., 2011; Strassels, 2009).  As a result of the extensive healthcare 
resource utilization among abusers, a case-control study found that as compared to non-
abusing citizens, the mean annual direct healthcare costs estimated for opioid abusers 
were more than 8.7 times higher than for nonabusers (White et al., 2005).  Similarly to 
the adverse health consequences of abuse, much of the economic burden of abuse can be 
attributed to opioids.  Hansen et al (2011) found that five controlled substance drugs, 
OxyContin®, oxycodone, hydrocodone, propoxyphene, and methadone, accounted for 
two-thirds of the total economic cost associated with abuse (Hansen et al., 2011).  With 
increasing rates and prevalence of abuse, the societal burden associated with prescription 
drug abuse costs may reach astronomical levels in the coming years. 
 
1.5 CONTRIBUTING FACTORS TO PRESCRIPTION DRUG ABUSE AND 
DIVERSION 
 
 Prescription drug misuse, abuse, and diversion is a complex and multi-faceted 
problem, occurring as the result of both legitimate and illegitimate means.  There are 
multiple contributors to the problem, such as a belief by many individuals that 
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prescription drugs are not dangerous (National Institute on Drug Abuse, 2014a); an 
increase in the availability of controlled substances on the market (Kaye, Vadivelu, & 
Urman, 2014); inappropriate prescribing (U.S. Department of Health and Human 
Services, 2013); and the use of multiple providers to obtain prescriptions (Centers for 
Medicare & Medicaid Services, 2014).  
 
1.5.1 PERCEPTIONS ABOUT SAFETY 
  
 One major factor that is believed to contribute to prescription drug and opioid 
abuse are patient perceptions that opioids are safer than illicit drugs because they are 
prescribed by doctors (Condon, 2012).  Many individuals do not understand or are not 
educated by their healthcare providers that certain prescription medications (i.e., opioids) 
may affect the brain in ways very similar to that of illicit drugs.  For example opioid pain 
relievers attach to the same cell receptors targeted by illegal opioids, such as heroin, and 
achieve their medicinal effects by acting on the same neurotransmitter systems as cocaine 
(National Institute on Drug Abuse, 2014a).  Individuals may also misuse prescription 
medications inadvertently by concurrently using them with alcohol or other 
contraindicating medications or taking them at too high of a dose for too long.  All of 
which can lead to an increased risk of dependence and negative health consequences, 
including death (Agency for Healthcare Research and Quality, 2013; Gudin, Mogali, 
Jones, & Comer, 2013). 
 
1.5.2 OVER PRESCRIBING AND AVAILABILITY 
 
 The U.S. has seen a dramatic increase in in the number of prescriptions written 
and dispensed for opioids in the past quarter century (Figure 1.4) (IMS Institute for 
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Healthcare Informatics, 2014).  Alarmingly, The International Narcotics Control Board 
has reported that the U.S. is actually the largest consumer of opioids worldwide, 
accounting for almost all hydrocodone consumption (99%) and the vast majority of 
oxycodone consumption (83%) (International Narcotics Control Board, 2013). 
 
Figure 1.4. National Utilization and Trends of Opioid Prescriptions Dispensed by 
U.S. Retail, Years 1991-2013 
 
 
Source: IMS Health, Vector One 2014 
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 Healthcare providers wrote 259 million prescriptions for opioid painkillers in 
2012, an amount estimated to be enough for every American adult to have their own 
bottle of painkillers (Centers for Disease Control and Prevention).  This equivocates to 
medicating every American adult with a dose of 5 mg of hydrocodone every 4 hours for 
one month (LJ Paulozzi et al., 2011).  Hydrocodone-combination painkillers were the 
most commonly prescribed drugs in the U.S. in 2013, accounting for 130 million 
prescriptions, and have been for the past five years (Table 1.4) (IMS Institute for 
Healthcare Informatics, 2014).   
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Table 1.4. Top Medications Dispensed in the U.S. by Number of Prescriptions 
Medication 2009 2010 2011 2012 2013 
acetaminophen/hydrocodone 129.4 132.1 136.7 136.4 129.2 
levothyroxine 100.2 103.2 104.7 112.2 115.2 
lisinopril 83.0 87.6 88.8 99.1 101.5 
metoprolol 76.9 76.6 76.3 82.6 83.9 
simvastatin 84.1 94.4 96.8 89.3 79.1 
Source: IMS Health, National Prescription Audit, 2013  
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 Higher prescribing and availability of opioid painkillers has been found to be 
positively associated with higher rates of overdose deaths (Centers for Disease Control 
and Prevention, 2014c; Manchikanti, Fellows, Ailinani, & Pampati, 2010).  A strong 
correlation (p<0.001) between increasing daily opioid dose, admission rates (Reisman, 
Shenoy, Atherly, & Flowers, 2009), and overdose risk has been revealed by several 
studies (Bohnert et al., 2011; Dunn et al., 2010; Gomes, Mamdani, Dhalla, Paterson, & 
Juurlink, 2011).  Dunn et al. (2010) found that as compared to patients receiving 1-20 mg 
of opioids per day, patients receiving 100 mg or greater had an 8.9 fold increase in the 
odds of overdose risk (95% CI=4.0-19.7).  Current clinical practice guidelines generally 
recommend prescribers to first consider alternatives to opioids, both pharmaceutical and 
nonpharmaceutical, for their chronic non-cancer pain patients, and then to start with 
lower dose, short-acting opioids (Centers for Disease Control and Prevention, 2014b).  
However, recent trends in prescribing have shifted towards prescribing long-acting opioid 
formulations as well as increased average daily dose (Boudreau et al., 2009; Franklin et 
al., 2011; T  Gomes et al., 2011). 
 Almost all prescription drugs involved in overdoses come from prescriptions 
originally prescribed by doctors and obtained from pharmacies, and not from illegitimate 
reasons such as being purchased online or stolen from pharmacies (Centers for Disease 
Control and Prevention, 2013b; Substance Abuse and Mental Health Services 
Administration, 2014a).  Given that 21.2% of individuals who reported abusing opioid 
pain relievers nonmedically cited having received them from one doctor and 53% cited 
that a friend/relative was their source (of which 83.8% of those individuals reported 
obtaining from one doctor) (Figure 1.5), individual doctors appear to be a main 
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contributing source of prescription pain relievers for abusers (Substance Abuse and 
Mental Health Services Administration, 2014a).   
 
 
Figure 1.5. Source Where Opioid Pain Relievers Were Obtained for Most Recent 
Nonmedical Use Among Past Year Users Aged 12 or Older: 2012-2013 
 
 
Source: SAMHSA, 2014 
 
 The majority of pain relievers used for non-medical reasons originated from one 
or more doctors, however several studies that found that only a small percentage of 
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prescribers are responsible for prescribing the majority of opioids (K Blumenschein et al., 
2010; Iyengar & Henderson, 2014; Oregon Health Authority, 2013; Swedlow, Ireland, & 
Johnson, 2011).  Data from the Oregon Prescription Drug Monitoring Program found that 
59% of the controlled substance prescriptions written in the state in 2012 were by the top 
2,000 prescribers, representing only 4.1% of the state’s prescribers (Oregon Health 
Authority, 2013).  Swedlow et al. (2011) also found that 3% of physicians accounted for 
55% of all Schedule II prescriptions prescribed in their study.  Nationwide a recent study 
from Express Scripts® found that 40% of U.S. narcotic prescriptions between 2011-2012 
were written by only 5% of opioid prescribers (Iyengar & Henderson, 2014).  Therefore a 
small percentage of high-volume prescribers can have a large impact on opioid use, abuse 
and overdose death rates.   
 
1.5.3 LACK OF PRESCRIBER EDUCATION 
  Concerns have been raised that only a small percentage of high volume 
prescribers are registered as pain specialists, who are ideally most suited to manage pain 
conditions and prescribe controlled pain medications.  However as of July 2014 there 
were currently only 2,300 board certified physicians in pain medicine (American Board 
of Pain Medicine, 2014).  It should be dually and especially noted that overprescribing 
and failure to adequately address chronic pain and explore alternative therapies is not 
completely at the fault of primary care physicians.  Primary care is often the main 
treatment modality for patients with pain, however primary care is often organized in a 
way that rarely allows clinicians time to perform comprehensive patient pain assessments 
and develop individualized treatment plans for each patient (Upshur, Luckmann, & 
	   28	  
Savageau, 2006).  Moreover, many health professionals lack training and education in a 
pain management role and appropriate opioid prescribing, not to mention that there is 
little reimbursement for their additional efforts (Institute of Medicine, 2011).  Given that 
chronic pain is one of the most prevalent conditions in the U.S., additional healthcare 
provider training in this area is warranted.   
 However, what is of concern is a lack of action on behalf of healthcare providers 
when aberrant behavior is suspected or detected among their patients.  A cohort study 
from 2011 found that when aberrant behavior was detected through urine drug testing 
(UDT) among individual patients, 55% of providers actually continued to prescribe 
opioids, with only 20% of prescribers discontinuing the therapy (Gupta, Patton, Diskina, 
& Cheatle, 2011).  Findings such as this may force the reexamination of where to target 
abuse prevention efforts and/or narrow efforts to educate the small percentage of 
prescribers contributing to the problem. 
 
1.5.4 ABBERANT CSP UTILIZATION BEHAVIORS 
 There are several aberrant behaviors that suggest CSP misuse or abuse that are 
readily identifiable by reviewing PDMP data.  Aberrant behavior can be defined as 
patient behaviors that may indicate prescription medication abuse or behaviors that are 
more likely to be associated with misuse/abuse (National Institute on Drug Abuse).  
Three aberrant behaviors discussed in this research include: receiving inappropriate 
and/or overlapping combinations of CSPs; utilizing multiple providers (i.e., doctor 
shopping) to obtain opioids and CSPs; and consuming a high daily morphine equivalents 
dose (MED).   
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1.5.4.1 SIMULTANEOUS OR OVERLAPPING CONTROLLED SUBSTANCE 
PRESCRIPTIONS  
 Utilization of opioids alone and in combination with benzodiazepines accounted 
for for almost half of the drug overdose deaths and three-fourths of drug-related ER visits 
in 2009 (Substance Abuse and Mental Health Services Administration, 2010b).  
Additionally, Wilsey et al. reported that individuals who had received stimulants and 
benzodiazepines simultaneously had a 20 times increase in odds ratio of utilizing multiple 
providers to obtain their prescriptions.  The same study reported that individuals who 
were prescribed a stimulant/anorectic, a benzodiazepine, and an opioid within the same 
month were 13 times more likely to utilize multiple providers to obtain CSPs (OR=13.12, 
95% CI=12.01-14.33), and 25.1 times increase (OR= 25.10, 95% CI=22.73-27.72) if the 
individual had simultaneous prescriptions for stimulants/anorectics, benzodiazepines and 
opioids (Wilsey et al., 2010).   
 
1.5.4.2 HIGH DAILY MORPHINE EQUIVALENT DOSE 
 Overdose deaths have been found to be highly correlated with a high average 
daily morphine equivalent dose (MED).  Measuring daily MED is a method of comparing 
doses across different opioids regardless of their formulation.(Boudreau et al., 2009; AM 
Gilson, Maurer, Ryan, Rathouz, & Cleary, 2013; Manchikanti, Abdi, et al., 2012; 
Prescription Drug Monitoring Program Training and Technical Assistance Center, 2013)  
The average MED morphine equivalent can be calculated using the following formula: 
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MME  Conversion  Formula:   (Drug  Strength)(Drug  Quantity)(MME  Conversion  Factor)Days  Supply  
 Current opioid dosing guidelines recommending that the daily dose of opioids for 
patients with chronic non-cancer pain should not exceed 120 mg of oral morphine 
(Agency Medical Directors Group, 2010).  However, Dunn et al. reported that as 
compared to patients receiving 1-20mg of opioids per day, those receiving 100mg or 
more per day had an 8.9 fold increase in overdose risk and a 1.8% annual overdose rate 
(Figure 1.6) (Dunn et al., 2010).  
 
Figure 1.6. National Utilization and Trends of Opioid Prescriptions Dispensed by 
U.S. Retail, Years 1991-2013 
 
Data Source: Dunn et al, 2010;  Image Source: Paulozzi, 2010 
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1.5.4.3 MULTIPLE PROVIDER EPISODES/DOCTOR SHOPPING 
 
 The CDC has recommended that prescription drug abuse prevention efforts focus 
resources on patients at highest risk in terms of prescription opioid painkiller dosage, 
numbers of controlled substance prescriptions, and numbers of prescribers (Centers for 
Disease Control and Prevention, 2013b).  This includes individuals who obtain 
prescriptions for the same drugs and/or controlled substances from multiple healthcare 
practitioners without the prescribers’ knowledge of the other prescriptions (Centers for 
Disease Control and Prevention National Center for Injury Prevention and Control 
Division of Unintentional Injury Prevention, 2012; McDonald & Carlson, 2013; Sansone 
& Sansone, 2012).  Patients in this category of prescription drug abuse are often 
classified as “doctor shoppers” or “pharmacy shoppers” and represent a significant 
contribution to diversion rates.   The author of this dissertation prefers the term ‘multiple 
provider episodes’ (MPE), given that shopping behavior occurs across healthcare 
providers (i.e., physicians and pharmacists).  However, the current literature utilizes both 
terms, therefore both terms will be used interchangeably throughout.  Additionally, the 
terms ‘doctor shopping’ and ‘pharmacy shopping’ have been found to be correlated and 
often interchangeable, given that the as the number of providers that a patient uses 
increases the number of pharmacies has been found to increase as well.  The term “doctor 
shopping” varies based on different definitions and indicators of questionable activity, 
such as: the numbers of pharmacies visited; numbers of prescribers used; prescriptions 
that are overlapping; using more than one class of controlled substance prescription from 
different providers; early refills of prescriptions; and excess of ‘standard’ doses over 
different periods of time.  These individuals often receive additional prescriptions for 
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medication than intended by their provider(s).  Some doctor shoppers may be obtaining 
multiple prescriptions to divert the medications to other individuals.  As documented 
from SAMHSA’s 2010 survey, over 75% of individuals who abuse prescription 
medications obtained them from someone else’s prescription (Substance Abuse and 
Mental Health Services Administration, 2011a). 
 As shown in Table 1.5, several studies have been conducted characterizing 
patients doctor and pharmacy shopping for controlled substances.  A variety of thresholds 
and different criteria were used to identify aberrant utilization in these studies.  Hall et al. 
characterized doctor shopping as obtaining prescriptions for controlled substances from 
five or more clinicians during the preceding year (Hall et al., 2008).  Whereas other 
studies used less specific standards and define doctor shopping as ‘patient consultation 
with multiple physicians in a short time frame with the explicit intent to deceive them in 
order to obtain controlled substances’ (Shaffer & Moss, 2010).  Therefore there is 
currently no “gold standard” definition for identifying aberrant behavior.
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Table 1.5. Definitions and Operationalization of Doctor and Pharmacy Shopping in the Literature 
Study Operational Definition Findings 
Prevalence and determinants of pharmacy shopping 
behavior (Buurma et al., 2008) 
Non-shopper: 1 pharmacy 
Light: >1 pharmacy 
Moderate: 3-4 pharmacies and proportion 
of prescriptions elsewhere >10% and 
number of prescriptions elsewhere >10 
Heavy: >5 pharmacies, proportion of 
prescriptions elsewhere >10% and 
number of prescriptions elsewhere >10 
Even light shopping behavior may put the patient at risk for 
unintentional drug-related problems 
Usefulness of prescription monitoring programs for 
surveillance--analysis of Schedule II opioid prescription 
data in Massachusetts, 1996-2006 (Katz et al., 2010) 
>4 pharmacies and >4 prescribers for any 
Schedule II drug 
or  >2 pharmacies and >2 prescribers for 
the opioid product in question 
The greater number of providers used, the greater the number of 
pharmacies used 
Time Series Analysis of California’s Prescription 
Monitoring Program: Impact on Prescribing and 
Multiple Provider Episodes (Gilson et al., 2012) 
Receiving prescriptions for the same 
medication from 2 or more practitioners 
within a 30-day period 
Multiple provider episodes represented almost 10% of all Schedule 
II opioid prescriptions issued during the 7-year study period 
Doctor and Pharmacyf Shopping for Controlled 
Substances. (Peirce et al., 2012) 
≥4 doctors in 6 months-doctor shopping 
≥4 pharmacies in 6 months-pharmacy 
shopping 
 
25.21% of individuals who had died from a drug-related death were 
identified as doctor shoppers; 20.23% of doctor shoppers were also 
pharmacy shoppers, and 55.60% of pharmacy shoppers were doctor 
shoppers 
Patterns of abuse among unintentional pharmaceutical 
overdose fatalities (Hall et al., 2008) >5 clinicians in year before death 
Most overdose deaths involved opioid analgesics; 21.4% deaths 
involved doctor shopping 
Distance Traveled and Frequency of Interstate Opioid 
Dispensing in Opioid Shoppers and Nonshoppers 
(Cepeda et al., 2013) 
Shopper: filled overlapping opioid 
prescriptions written by >1 prescriber at 
≥3 pharmacies. 
Heavy shopper: ≥5 shopping episodes 
Opioid shoppers travel greater distances and more often cross state 
borders to fill opioid prescriptions than nonshoppers, and their 
dispensings accounted for a disproportionate number of opioid 
dispensings 
Profiling multiple provider prescribing of opioids, 
benzodiazepines, stimulants, and anorectics (Wilsey et 
al., 2010) 
Receiving a prescription for the same 
medication from ≥2 practitioners filled by 
≥2 pharmacies within a 30-day period. 
Opioid prescriptions (12.8%) were most frequently involved in 
multiple provider episodes and patients with simultaneous categories 
of controlled substances 
Shopping Behavior for ADHD Drugs: Results of a 
Cohort Study in a Pharmacy Database (Cepeda et al., 
2014) 
≥1 overlapping prescription written by ≥2 
prescribers filled by ≥3 pharmacies 
Shopping episodes occurred 4 times more frequently in the ADHD 
cohort than those in comparison asthma cohort 
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 Consequently, the lack of a standard definition for doctor shopping, and the wide 
variation across studies, may result in the unintended consequence of a high risk for both 
false positives and negatives.  Using criteria that is not stringent enough in its criteria 
(e.g., ≥ 3 doctors and/or  ≥ 3 pharmacies) may lead to the misclassification of patients 
who may actually be using opioids appropriately, resulting in false positives for doctor 
shopping.  However, increasing this criteria to be too lenient (e.g., ≥ 5 doctors and/or  ≥ 5 
pharmacies) may result in excess false negatives and missed opportunities to identify 
individuals with apparent behavior (Katz et al., 2010).  The uncertainty with identifying 
doctor shopping individuals may also be elevated due to the fact that most PDMPs are 
not linked with patient medical records, which may verify that a patient has a diagnosis 
warranting excessive controlled substance use.  Consequently, in settings such as 
community pharmacies where pharmacists may not have access to patient records, 
identifying doctor shoppers may be challenging and problematic.  Therefore, clinical 
expertise should be consulted before setting specific doctor shopping thresholds, as well 
as conducting sensitivity analysis based on the specific objectives of the study.  Katz et 
al. (2010) also recommends the use of both multiple providers and multiple pharmacies 
for defining ‘doctor shopping’ (Katz et al., 2010), hence the term ‘multiple provider 
episodes’. 
 While defining doctor shopping is problematic, healthcare providers are also 
faced with the issue of what to do if a patient is suspected of doctor shopping.  In West 
Virginia, where prescription drug overdose rates are the highest in the nation, a physician 
survey reported that while 40% of responding physicians suspected a patient of doctor 
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shopping at least once a week, only 22% were presently reporting doctor shopping.  
However, 85% of physicians responded that they would be likely to report doctor 
shopping if there was a law granting immunity to physicians for reporting doctor 
shoppers in good faith to law (Shaffer & Moss, 2010). 
 
1.6 PREVALENCE OF DOCTOR SHOPPING 
 Prevalence estimates of doctor shopping vary by state and depend on the 
definition of doctor shopping.  Based on prescription drug monitoring data in Kentucky, 
doctor shopping estimates were 18% between 2001-2002 (Manchikanti et al., 2003) and 
9% in 2005 (Manchikanti et al., 2006).  A 2012 follow up study found that doctor 
shopping rates had fallen to 2.1% (Manchikanti, Pampati, et al., 2012).  While exact 
prevalence rates were not reported, an Ohio study of 179 participants in an emergency 
department setting found that among the patients involved in the study the number of 
opioid prescriptions that individuals had ranged from 0 to 128 within a 12-month period, 
with prescriptions in some cases being obtained from up to 40 different physicians (D 
Baehren et al., 2010).  Within the California Controlled Substance Utilization Review 
and Evaluation System (CURES) PDMP database, two different studies found incidence 
rates of doctor shopping to be 8.4% (Wilsey et al., 2010) and 9.5% of all prescriptions 
involving opioids (AM Gilson, Fishman, Wilsey, Casamalhuapa, & Baxi, 2012).  While 
only a small percentage of individuals meet the criteria for doctor shopping, these 
individuals account for a disproportionately large number of opioid prescriptions 
dispensed.  A recent retrospective cohort study found that while doctor shoppers only 
accounted for 0.7% of the subjects in the study, they consumed 8.6% of all opioids 
	   37	  
dispensed (Cepeda, Fife, Yuan, & Mastrogiovanni, 2013).  McDonald and Carlson (2013) 
also reported that extreme doctor shoppers only account for 0.7% of the patient 
population in a national study, however they bought 1.9% of all opioid prescriptions (4% 
weighted to national population). 
 
1.7 CHARACTERISTICS ASSOCIATED WITH DIVERSION AND DOCTOR 
SHOPPING 
 
 Research has shown that certain factors may make individuals or groups 
particularly vulnerable to prescription drug abuse and misuse, including underlying 
demographic, socioeconomic, geographic, and clinical factors.  Understanding the factors 
associated with abuse and diversion is important in identifying the individuals and 
populations at highest risk for abuse and doctor shopping activities, as well as for the 
creation of interventions targeting these individuals. 
 
1.7.1 INDIVIDUAL LEVEL CHARACTERISTICS ASSOCIATED WITH 
DIVERSION AND DOCTOR SHOPPING 
 
 Individual characteristics have been found to be strong predictors of nonmedical 
use of prescription medications, particularly opioids, as well as doctor shopping behavior 
(Buurma et al., 2008; Fishman, 2010; Han, Kass, Wilsey, & Li, 2012; Jones, 2012; 
Wilsey et al., 2010). As was found with chronic nonmedical use of opioids (Jones, 2012) 
and emergency room admissions for nonmedical use of opioids (Figure 1.7) (Substance 
Abuse and Mental Health Services Administration, 2010a), several studies have found 
that using multiple pharmacies and prescribers is associated with younger age (i.e., 18-25 
years of age) (Buurma et al., 2008; Fishman, 2010; Han et al., 2012; Peirce et al., 2012; 
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Wilsey et al., 2010).  However, the probability of being admitted for treatment involving 
opioid pain reliever abuse has been found to increase with age (Simeone, Holland, & 
Simeone Associates, 2006).  Additionally, the rate of drug overdose deaths was found to 
be highest among individuals between the ages of 45-54 (Centers for Disease Control and 
Prevention, 2012).   
 
Figure 1.7. Age-specific Rates of Emergency Department Visits for Nonmedical Use 
of Opioid Analgesics (OAs) and Benzodiazepines (BZDs) — United States, 2004 and 
2008 
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Source: SAMHSA, 2010 
 Gender has also been found to play a role in both abuse of controlled substance 
prescriptions and doctor shopping behaviors.  While the literature has revealed 
conflicting reports of the association between gender and opioid abuse, it is believed that 
males are more likely to abuse prescription drugs and develop substances disorders 
(Eaton et al., 2011; National Institute on Drug Abuse, 2014b).  However, as shown in 
Figure 1.8 the rate at which females are abusing prescription medications, particularly 
opioids, is growing exponentially, and the use of multiple provider episodes is more 
frequent among females (Han et al., 2012).  The rate at which women are dying from 
prescription painkiller overdoses has increased 400% since 1999 for women and 265% 
for males, or about 18 women per day (Centers for Disease Control and Prevention, 
2013a).  The Drug Abuse Warning Network (DAWN) has also reported that 
approximately every three minutes a woman goes to the emergency department for 
prescription opioid misuse or abuse (Substance Abuse and Mental Health Services 
Administration, 2013).  A survey using the National Household Survey on Drug Abuse 
(NHSDA) revealed that females have a 43% increased odds of any past-year prescription 
drug nonmedical use as compared to males (OR=1.43, 95% CI=1.19–1.69) (Simoni-
Wastila, Ritter, & Strickler, 2004).  Rosenblum et al. found that women were more likely 
than men to abuse prescription opioids in the past 30 days (Rosenblum et al., 2007).  
Females have also been found to have the greatest number of claims for opioid analgesics 
(Curtis et al., 2006).  Studies from Buurma et al. and Hall et al. have found a greater risk 
of doctor shopping behaviors among females (OR=1.2, 95% CI=1.1-1.2; OR=2.2, 95% 
CI=1.2-4.1), respectively (Buurma et al., 2008; Hall et al., 2008).  The literature has also 
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reviled that females also have higher probabilities of admission involving abuse 
(Simeone et al., 2006).  
 
Figure 1.8. Prescription Painkiller Overdose Deaths Among Women 
 
 
Source: National Vital Statistics System, 1999-2010 
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 Certain socio-economic factors, such as full-time employment status, have been 
found to reduce the probability of admission involving abuse (Simeone et al., 2006).  An 
individual’s insurance status may also increase the likelihood of developing opioid abuse, 
as insurance status is often an indicator of both an individual’s socioeconomic and health 
status (Bonito, Bann, Eicheldinger, & Carpenter, 2008).  An analysis of chronic opioid 
use among commercially insured individuals and Medicaid patients, found that chronic 
use was more prevalent among Medicaid patients (Edlund et al., 2010).  In Kentucky 
28.6% of individuals identified as doctor shoppers had Medicaid as their form of 
insurance coverage, as compared to 14.3% insured by a third party (Manchikanti, 
Pampati, et al., 2012). 
 The number and type of prescriptions for controlled substances that a patient has 
is found to be positively associated with doctor shopping behavior (Fishman, 2010; Hall 
et al., 2008; Han et al., 2012; Katz et al., 2010; Kim, Small, Hwang, & Muldrew, 2014; 
Rosenblum et al., 2007; White et al., 2005; Wilsey et al., 2010).  A case-control study 
conducted by Wilsey et al. (2010) using the California CURES database found that 
among the 8.5% of the study population that were identified as ‘doctor shoppers’, opioid 
prescriptions were the most frequently involved prescription (12.8%).  Additionally, odds 
ratios for multiple provider prescribing increased exponentially when more than one 
controlled substance class was prescribed.  The study reported that individuals who were 
prescribed stimulant/anorectic and benzodiazepines along with an opioid during the same 
30 days had a 13 times increase in probability of multiple provider prescribing 
(OR=13.12, 95% CI=12.01-14.33), and 25.1 times increase (OR= 25.10, 95% CI=22.73-
27.72) if the individual had simultaneous prescriptions for stimulants/anorectics, 
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benzodiazepines and opioids (Wilsey et al., 2010).  Han et al. (2012) found that as 
compared to using just Schedule II controlled substance prescriptions, individual’s who 
used both Schedule II and III opioids utilized more prescribers and pharmacies 
(OR=3.02, 95% CI=2.98-3.06).  When analyzing a cohort of only Schedule II drugs, Katz 
et al. (2010) found that oxycodone was the opioid most highly associated with 
questionable activity.  Also in analyzing prescription opioid abuse among enrollees in a 
methadone maintenance treatment, Rosenblum et al (2007) reported that the most 
frequently abused prescription opioids among the abusers in their lifetime were 
oxycodone (89%), hydrodocone (88%) and morphine (59%).  An increased risk has also 
been found for individuals with ≥ 3 prescriptions (Buurma et al., 2008), use of long-
acting opioids, use higher total daily drug doses, and use oxycodone, morphine, and 
fentanyl (Kim et al., 2014).  In West Virginia 21.4% of individuals who had died of an 
overdose had received prescriptions for controlled substances from 5 or more clinicians 
during the year prior to their death (Hall et al., 2008).  In Maine using prescription claims 
data, White et al found that having 12 or more opioid prescriptions in three months 
resulted in an over twofold (OR=2.12, 95% CI=1.73-2.61) increase of risk of overdose 
(White, Birnbaum , Schiller, Tang, & Katz, 2009).  Using data collected from the 
California CURES database, a preliminary, unpublished analysis from Fishman (2010) 
found that the likelihood of an individual receiving opioids from more than one provider 
doubled if they also had a prescription for an additional controlled substance prescription.  
Additionally, the likelihood of doctor shopping increased by 13 times if the individual 
received three or more prescriptions for different schedules of medications. 
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1.7.2 REGIONAL LEVEL AND SOCIODEMOGRAPHIC CHARACTERISTICS 
ASSOCIATED WITH DIVERSION AND DOCTOR SHOPPING 
 
 While it is individuals who abuse controlled substances, regional-level 
characteristics and population-specific demographics that vary by communities, counties 
and states, are believed to influence individual behavior and potential for an increased 
risk of abuse (Fishman, 2010; Han et al., 2012; PDMP Center of Excellence, 2012; 
Simeone et al., 2006).  Local public health authorities can better understand and 
efficiently serve populations through resource allocation, prevention and treatment efforts 
if they know the distribution and prevalence of nonmedical use of prescription drugs in 
certain regions (e.g., metropolitan, urbanized non-metropolitan, and rural). 
 Geographical location may play an important role in aberrant prescription drug 
use.  Previous research has indicated that variances in regulations, policies and even 
diverse populations by geographic location affect not only opioid and CSP use, but also 
abuse (Curtis et al., 2006).  Wilsey et al found that smaller populated counties were 
associated with a decreased likelihood of having multiple prescriber episodes, as 
compared to metropolitan areas with greater than one million people (Wilsey et al., 
2010).  A study from Fishman also reported a positive association between doctor 
shopping behavior and residence in metropolitan areas (Fishman, 2010).  The findings 
from these studies are supported by the results of the National Surveys on Drug Use and 
Health (NSDUH) from 2005-2011 (Table 1.6), which found that individuals located in 
metropolitan and urbanized counties reported higher rates of nonmedical use within the 
past year, as compared to rural citizens.  Certain CSP are also more frequently involved 
in multiple provider episodes by geographical location.  Wilsey et al. found that 
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benzodiazipines were more prevalent in MPE cases in larger urban areas (Wilsey et al., 
2010).  However, rates were similar across all three county types for past month use 
(Substance Abuse and Mental Health Services Administration, 2014a).  Nonetheless, 
nonmedical use of prescription medications remains a concern across all county types. 
 
Table 1.6. Past Year and Past Month Nonmedical Use of Prescription-Type 
Drugs among Persons Aged 12 or Older, by County Type: 2005 to 2011 
County Type Past Year Past Month 
Metropolitan 6.4% 2.7% 
Urbanized Non-
metropolitan 6.6% 
2.8% 
Rural  5.4% 2.4% 
Source: SAMHSA, National Surveys on Drug Use and Health (NSDUHs), 2014 
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 A multi-level modeling approach to defining abuse by state-level factors found 
that the probability of prescription stimulant abuse is a function of the per capita supply 
of prescription stimulants.  This study also found that increasing the supply of opioid pain 
relievers in a state increases the probability of admission to treatment involving pain 
reliever abuse; and increasing the supply of stimulants increases the probability of 
admission to treatment involving stimulant abuse (Simeone et al., 2006). 
 A nationwide study of counties also found a positive association between the 
number of surgical specialists in and area the and the number of claims for opioid 
prescriptions (Curtis et al., 2006).  Analyzing individual-level and county-level factors 
associated with multiple provider episodes in California, Han et al found that the total 
number of licensed physicians and surgeons in a county was linearly associated with 
multiple provider episodes (Han et al., 2012).  Other factors that have been found to be 
positively correlated with prescription opioid drug rates are both poverty and 
unemployment rates (Spiller, Lorenz, Bailey, & Dart, 2009).  
 
1.8 CONSEQUENCES OF DOCTOR SHOPPING 
 Recent research has found an association between shopping behavior and an 
increased risk for drug-related death (T Gomes et al., 2011; Hall et al., 2008; Peirce et al., 
2012).  One such factor associated with doctor shopping is the lack of continuity of care 
within and across providers.  Discontinuity of care increases the risk of medication errors 
and poor clinical outcomes, inhibits appropriate patient medication surveillance (Buurma 
et al., 2008; Moore, Wisnivesky, & McGinn, 2003; Van Walraven, Mamdani, & Austin, 
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2004) and increases the risk for drug–drug interactions (Buurma et al., 2008).  The risk of 
a potentially inappropriate drug combination has been found to increase with the number 
of prescribing physicians (Tamblyn, McLeod, Abrahamowicz, & Laprise, 1996; 
Vingerhoets, Wieringa, Egberts, Jansen, & Jansen, 2014).  As discussed by Vingerhoets 
et al. (2014) most doctors do not have a complete overview of all the medicines 
prescribed or used by patients and often do not have sufficient time or knowledge to 
evaluate polypharmacy, therefore the increasing number of doctors utilized contributes to 
inappropriate prescribing.  However, use of a single primary care physician and a single 
dispensing pharmacy may offer "protective" effects by lowering the risk of potentially 
inappropriate drug combination (Tamblyn et al., 1996).  A study conducted in the 
Netherlands concluded that even light shopping behavior (>1 pharmacy) may impede 
appropriate medication surveillance and put patients at risk for unintentional drug 
therapy-related problems, such as duplicate medications, drug–disease interactions and 
drug–drug interactions (Buurma et al., 2008). 
 
1.9 DOCTOR SHOPPING LAWS 
 As of 2012 only 16 states have ‘specific’ fraud statutes pertaining to doctor 
shopping (Figure 1.9).  Specific doctor shopping laws prohibit patients from not 
disclosing to their healthcare practitioners that they have received: a controlled substance 
or prescription order from another practitioner; the same controlled substance or of 
similar therapeutic use within a specified time interval or at any time previously (Centers 
for Disease Control and Prevention National Center for Injury Prevention and Control 
Division of Unintentional Injury Prevention, 2012).   The other 34 states have ‘general’ 
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statutes, derived from the Uniform Narcotic Drug Act of 1932 or the Uniform Controlled 
Substances Act of 1970.  The majority of general statutes refer to doctor shopping as 
obtaining drugs through fraud, deceit, misrepresentation, subterfuge, or concealment of 
material fact and non-disclosure (Centers for Disease Control and Prevention National 
Center for Injury Prevention and Control Division of Unintentional Injury Prevention, 
2012),(The National Alliance for Model State Drug Laws (NAMSDL), 2010). 
 
Figure 1.9. States with Doctor Shopping Laws 
 
 
Source:  CDC, 2012 
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1.10 APPROACHES TO ADDRESSING DIVERSION AND DOCTOR SHOPPING 
 
 In response to the escalating problem of prescription drug abuse, in recent years 
states across the U.S. have began implementing programs and policies to reduce 
prescription drug abuse.  However, few tools or programs encompass more than one of 
the components of the Department of Health and Human Services (HHS) eight domains 
for addressing drug abuse activities: 1) surveillance, 2) drug abuse prevention, 3) patient 
and public education, 4) provider education, 5) clinical practice tools, 6) regulatory and 
oversight activities, 7) drug abuse treatment, and 8) overdose prevention initiatives.  
However, one program has utility in each of these domains and the Department of Health 
and Human Services has referred to it as “one of the most promising clinical tools to 
address prescription drug abuse” (U.S. Department of Health and Human Services, 
2013). This tool is state prescription drug monitoring programs. 
 
 
1.10.1 PRESCRIPTION DRUG MONITORING PROGRAMS (PDMPS) 
 
 Prescription drug monitoring programs (PDMPs) are statewide electronic 
databases which collect designated data on controlled substances prescriptions and 
certain noncontrolled substances (e.g., tramadol) dispensed within the state (U.S. 
Department of Justice Drug Enforcement Administration Office of Diversion Control, 
2011).  Currently, 49 states, the District of Columbia and one U.S. territory (Guam) have 
authorized legislation for the creation and operation of a state PDMP (Figure 1.10).  
Forty-eight states and Guam currently have a PDMP that is operational.  Operational 
status means that the program is currently collecting data from dispensers and reporting 
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information from the database to authorized users (The PDMP Training and Technical 
Assistance Center, 2014). 
 
Figure 1.10. Status of State Prescription Drug Monitoring Programs 
 
Source: The National Alliance for Model State Drug Laws, 2014 
 
 Prescription drug monitoring programs were first established in 1939 in the State 
of California.  Based in the Department of Justice, the program was designed to monitor 
prescriptions for Schedule II controlled substances for law enforcement purposes.  During 
this time state-issued paper triplicate and serialized prescription forms were used, lasting 
up until the late 1990s.  Starting in the 1990s PDMPs starting incorporating advances in 
the technology and functionality of PDMPs, with electronic submission of prescription 
data increasing the accuracy and timeliness of submissions.(PDMP Training and 
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Technical Assistance Center, 2012)  Most state PDMPs now have secure online portals 
for authorized providers to access patient PDMP data.  In 1995, Nevada became the first 
state to require collecting prescription data for Schedule II-IV drugs.  The introduction of 
the Harold Rogers Prescription Drug Monitoring Programs Grant in 2003 provided 
funding and support for the creation of 33 new state PDMPs (Clark, Eadie, Kreiner, & 
Strickler, 2012; PDMP Training and Technical Assistance Center, 2012).    
 
1.10.2 CHARACTERISTICS OF PDMPS 
 
 Individual states vary in how the monitoring programs are operated.  This 
includes their objectives, design, which schedules of controlled substances they monitor, 
who can access the data, the frequency of reporting data and which state agency houses 
the PDMP (Finklea, Sacco, & Bagalman, 2014).  PDMPs serve a variety of functions 
across different states, but all are ultimately intended to promote legitimate access to 
controlled substances and reduce the abuse of controlled substance pharmaceutical drugs 
(Finklea et al., 2014; A Gilson, Husain, Payne, & Twillman, 2013; Simeone et al., 2006).  
PDMPs can function to address prescription drug abuse by improving patient care 
through the quick identification of high-risk patients, providing complete prescription 
history information to emergency department providers, and conveying current and 
accurate information to guide appropriate clinical decision making for both physicians 
and pharmacists (U.S. Department of Health and Human Services, 2013).   
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1.10.3 SOLICITED AND UNSOLICITED REPORTING 
 
 State PDMPs can also be classified as a reactive or proactive system based on 
how the state generates reports based on PDMP data to authorized users (K  
Blumenschein et al., 2010; Simeone et al., 2006).  Solicited reports, also known as 
reactive reporting, are provided to authorized users upon on their request for more 
information (e.g., pharmacists).  Authorized users vary by state, but include prescribers, 
dispensers, law enforcement, and regulatory boards.  Unsolicited reporting, also referred 
to as proactive reporting, produces reports to authorized individuals based on pre-
established thresholds established by the individual PDMP (PDMP Training and 
Technical Assistance Center, 2013a).  Unsolicited reporting may be triggered if analysis 
of PDMP data indicates potential questionable activity either by a patient or a prescriber.  
This includes sending reports to prescribers and pharmacists to notify them that a patient 
may potentially be doctor shopping or diverting controlled substances or to notify 
investigative agencies and professional licensing boards that a prescriber may be 
prescribing inappropriately or excessively (Astho, 2014; Centers for Disease Control, 
2013).  The Prescription Drug Monitoring Program Center of Excellence cites the 
unsolicited reporting of PDMP data to prescribers, dispensers, licensing boards, and law 
enforcement agencies as a PDMP best practice for states, as it helps to promote safe 
prescribing and limit diversion of controlled substances (PDMP Center of Excellence, 
2014c).  Unsolicited reporting of PDMP data has shown potential to improve clinical 
practice by alerting providers about patients with multiple prescribers and potentially 
medically unnecessary prescriptions (Thomas et al., 2014).  Simeone and Associates 
found that states which have PDMPs, particularly proactive PDMPs, have a reduced 
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supply of opioids and in so doing have an indirect effect on abuse rates (Simeone et al., 
2006). 
 Several components of reporting vary across state programs, including whether 
the program produces both solicited and unsolicited reports, the timeliness of generating 
reports to end users and the users who are authorized to receive these reports (Figure 
1.11) (National Council for Prescription Drug Programs, 2013). 
 
Figure 1.11. Status of Unsolicited Reporting 
 
Source: National Alliance for Model State Drug Laws, 2014 
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1.10.4 ADMINISTRATION OF PDMPS 
 
 PDMPs are housed in and operated by different governmental agencies, including 
health or human services departments, single state authority on drugs and alcohol, boards 
of pharmacy, law enforcement agencies, professional licensing agencies and consumer 
protection agencies (National Alliance for Model State Drug Laws, 2009).  However, the 
majority of PDMPs are operated by state boards of pharmacy (Figure 1.12) (K  
Blumenschein et al., 2010).  The housing of PDMPs has been a debated topic among 
stakeholders, with some organizations raising concerns about healthcare versus law 
enforcement uses of PDMP data (Finklea et al., 2014).  Both the American Medical 
Association (AMA) and the American Society of Addiction Medicine (ASAM) have 
recommended that PDMPs should be housed in health-related agencies, citing that PDMP 
data should be used for the purpose of educating providers, not for civil action against 
physicians.  Both organizations have also expressed concerns over agencies outside of the 
healthcare system accessing private personal identifiable information contained in the 
PDMP (AMA Advocacy Resource Center, 2012; American Society of Addiction 
Medicine, 2012).  Additionally, Fleming et al. reported that among law enforcement–
governed PDMPs, healthcare provider utilization was lower compared with PDMPs 
under health or pharmacy boards (ML Fleming, Chandwani, Barner, Weber, & Okoro, 
2013). 
 Other components of PDMPs that vary based on their administration and state 
laws are: the schedules of controlled substances that are monitored under each program; 
the extent of data that is collected by the program; the timeliness of submitting 
prescription information; and who is authorized to access the database (e.g., doctors, 
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pharmacists, law enforcement, state medical examiners, researchers) (Finklea et al., 
2014). 
 
Figure 1.12. PDMP Housing Entities 
 
Resource: National Alliance for Model State Drug Laws, 2014 
 
 
 
 
1.11 STRENGTHS OF PDMPS AND UTILIITY IN COMBATTING 
PRESCRIPTION DRUG ABUSE 
 
 Prescription Drug Monitoring Programs are currently being recognized as one of 
the key components to combatting prescription drug abuse (Kerlikowske, Jones, Labelle, 
& Condon, 2011; Office of National Drug Control Policy, 2013).  Data collected from 
PDMPs can be utilized as a public health surveillance tool given its utility in the ongoing, 
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systematic collection.  This public health tool can be used to reduce morbidity and 
mortality and to improve health outcomes (Centers for Disease Control and Prevention, 
2001).   Evidence is beginning to accumulate which illustrates that PDMPs are effective 
for law enforcement, improving clinical decision-making, reducing excessive controlled 
substance prescription prescribing, and reducing prescription drug abuse and doctor 
shopping. (Haffajee, Jena, & Weiner, 2015; PDMP Center of Excellence, 2014a; 
Simeone et al., 2006; U.S. General Accounting Office, 2002) 
 
1.11.1 UTILITY FOR EVALUATION PURPOSES 
 The inherent structure of data collected from state PDMPs is strong in its usefulness 
for evaluation and  research.  Most state PDMP databases include a high level of drug 
detail, including the drug name, formulation, prescriber, and dispenser identifications.  
PDMP data also have high statistical power, given that there are observations for millions 
of patients.  Patients, provider and pharmacy data can also be linked longitudinally across 
time (L Paulozzi, 2010).  PDMPs have also assisted law enforcement agencies and 
regulatory investigators by reducing the amount of time and effort required to explore 
leads in possible drug diversion cases.  In Nevada the state’s PDMP was found to reduce 
the investigation time of alleged doctor shoppers from approximately 120 days to 20 
days.  State drug control investigators in Kentucky reported taking an average of 156 
days to complete the investigation of alleged doctor shoppers before the state’s PDMP 
(KASPER) implementation, dropping down to 16 hours on average after its 
implementation (United States General Accounting Office, 2002).   
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1.11.2 REDUCE PRESCRIBING AND DISPENSING OF CONTROLLED 
SUBSTANCES 
 
 The presence of an active PDMP has been found to reduce the per capita supply of 
prescription pain relievers and stimulants, while also indirectly reducing the probability 
of abuse for such drugs (Reisman et al., 2009; Simeone et al., 2006).  Several states have 
reported success in using their state PDMPs as a tool in improving controlled substance 
prescribing practices.  Curtis et al found that while claims rates for opioids varies greatly 
across states, states with long-standing prescription monitoring programs had the lowest 
rates of claims for opioid analgesics and controlled-release oxycodone (Curtis et al., 
2006).  In New York State, mandatory utilization requirement of the state’s PMDP (I-
STOP) for prescribers resulted in and 9.51% decrease in the number of individuals with 
prescriptions for opioids (PDMP Center of Excellence, 2014b).  Following the inception 
Florida’s PDMP program (E-FORCSE®: Electronic-Florida Online Reporting of 
Controlled Substance Evaluation Program), prescribing of oxycodone and methadone fell 
by 24% and 8%, respectively, between 2011-2012 (Florida Health, 2013).  Other states 
reporting a decline in dispensing of opioids in the year following prescriber mandates to 
use their respective PDMPs were Tennessee (7% decline in opioids) and Kentucky (8.5% 
decrease in opioid prescriptions (PDMP Center of Excellence, 2014b). 
 
1.11.3 IMPROVING PATIENT CARE   
 One important element of PDMPs is their function as a clinical-decision making 
tool for healthcare providers.  Most PDMPs provide of a complete record of a patient’s 
controlled substance prescribing history for a designated amount of time, enhancing 
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patient safety by enabling a provider to avoid potentially deadly combinations of 
medications (A Gilson et al., 2013).  An example of what a patient profile might look like 
is provided in Figure 1.13. 
 PDMP data can help inform appropriate clinical decision-making and give 
healthcare providers confidence to ensure that prescriptions are medically necessary 
(PDMP Center of Excellence, 2014a).  Several studies have recently been conducted 
analyzing provider use of state PDMPs, showing the clinically appropriate action that 
was taken by providers after reviewing PDMP data. 	  In Ohio Baehren et al. reported that 
in an emergency department setting, the use of Ohio’s PDMP (OARRS) data influenced 
the provider’s opioid prescribing pattern. After reviewing PMDP data, providers changed 
their clinical management plan in 41% of the cases.  Within those cases 61% of the study 
patients were prescribed fewer or no opioid medications than had been originally 
planned, and 39% of patients received more opioid medication than originally planned (D 
Baehren et al., 2010).  Also in Ohio 89% of attending physicians and residents cited 
utilizing the OARRS database when they had concerns about prescription drug abuse 
(Feldman, Skeel Williams, Knox, & Coates, 2012). 	  In a second study of emergency 
providers, physician exposure to PDMP data resulted in changed plans to prescribe 
opioids at discharge in 9.5% of cases, some of which receiving opioids not previously 
planned (Weiner et al., 2013).  In an Indiana survey, 50.1% of prescribers reported 
changing their treatment plan for a patient based on PDMP data and over 90% stated that 
as a result they had prescribed fewer controlled substances (Kooreman, Carnes, & 
Wright, 2014).  In Oregon providers who were active users of the Oregon Prescription 
Drug Monitoring Program (PDMP) reported haven spoken with a patient about controlled 
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substance use (78%), confirmed patient not misusing prescriptions (68%), confirmed 
patient was doctor shopping (59%) and/or reduced or eliminated prescriptions for a 
patient (59%) (Multnomah County Health Department and Oregon Health Authority, 
2013).	  
 
Figure 1.13. Example of Patient PDMP Profile 
 
 
 
1.11.4 REDUCE PRESCRIPTION DRUG ABUSE AND DOCTOR SHOPPING 
 As data from ‘modern’ state PDMPs begins to be collected, studies are beginning 
to analyze PDMPs and their utility in identify potential doctor and pharmacy shoppers, 
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both retrospectively and at the point of care (Manchikanti, Pampati, et al., 2012; Peirce et 
al., 2012).  A prescriber survey in Massachusetts found that when prescribers received 
unsolicited reports from the Massachusetts Prescription Monitoring Program (MA PMP) 
only 28 respondents (8.4%, of which most were oncology/hematology specialists) 
reported being aware of most, nearly all, or all prescribers listed in the report.  The survey 
reported that emergency department providers were the least aware of other prescribers 
(Thomas et al., 2014).  This study highlights the importance of using PMDPs as a tool for 
identifying potential doctor shopping behavior and assuring for the clinical 
appropriateness of controlled substances.  
 Several states have released recent reports of their state’s doctor shopping status 
as the result of PDMP utilization.  In Kentucky Manchikanti et al concluded that with the 
assistance of the state PDMP KASPER’s enhanced monitoring (Kentucky All Schedule 
Prescription Electronic Reporting) doctor shopping was reduced from 18% to 2.1% over 
a period of 10 years (Manchikanti, Pampati, et al., 2012).  Following a 2013 mandate 
requiring New York prescribers to use the state’s prescription drug monitoring program 
(I-STOP), the state saw a 75% decline in the number of patients obtaining painkillers 
from multiple prescribers (5 prescribers/5 pharmacies over 3 months) (PDMP Center of 
Excellence, 2014b).  In 2011 in Florida as the result of years of extensive 
overprescribing, dispensing, and prescription drug misuse, several initiatives were set 
forth to address the problem, including dispenser mandatory reporting to the state’s new 
PDMP (E-FORCSE®) (H. Johnson, Paulozzi, Porucznik, Mack, & Herter, 2014).   As a 
result Florida saw a 51% reduction in doctor shopping behavior (5 or more doctors or 
five or more pharmacies in 90 days) (Florida Health, 2013).  Other states reporting a 
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decline in doctor shopping rates post-PDMP implementation are Virginia (73% 
reduction) (Virginia Department of Health Professions, 2014) and Tennessee (36% 
reduction) (PDMP Center of Excellence, 2014b). 
A study from the Bouches-du-Rhoˆ ne region of France found a reduction of doctor 
shopping rates for buprenorphine, a medication generally used for opioid maintenance 
treatment, from 21.7% to 16.9% after the inception of its prescription monitoring 
program (Pradel et al., 2009).  
 
1.11.5 REDUCTION IN OVERDOSES AND RELATED DEATHS  
 While directly linking implementation of a state PMDP with a reduction in opioid 
overdoses and deaths has not been wholly established, states are reporting reductions in 
overdose rates post-PDMP implementation alongside other state prevention initiatives to 
reduce abuse rates.  In the year following a state overhaul of pain clinics and a mandate 
that prescribers use the KASPER system before prescribing many controlled substances, 
Kentucky saw a decline in prescription overdoses for the first time in over a decade 
(Governor’s Communication Office press release, 2013).  Following Florida’s 
implementation of E-FORCSE® in 2011, the state saw a oxycodone-related overdose 
deaths fall by 41% (Florida Health, 2013).  Alongside new pain management rules for 
healthcare providers, the Department of Health in Washington implemented its PDMP at 
the end of 2011 and saw overdose death rates drop by 27% (WA Department of Public 
Health press release, 2014). 
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1.12 PROBLEMS AND LIMITATIONS ASSOCIATED WITH PDMPS 
 As with the benefits associated with PDMP use, there is potential for unintended 
consequences of PDMPs, which have created debate among the program’s advocates and 
critics. 
 
1.12.1 UNDERUTILIZATION 
 While PDMPs may be an effective tool in identifying and deterring shopping 
behavior and aberrant use of prescription medications, they are widely underutilized in 
most states where use is not considered ‘mandatory’.  This type of program must be fully 
utilized to reach its full potential in controlling prescription drug abuse and diversion 
(Kerlikowske et al., 2011).  A 2012 study of Ohio resident physicians found that only 
51% of residents reporting utilizing the Ohio OARRS system (Feldman et al., 2012).  A 
2013 survey in Indiana reported that 23.1% of medical doctor (M.D.) respondents still 
hadn’t heard of the state’s PDMP ‘Indiana Scheduled Prescription Electronic Collection 
and Tracking Program’ (INSPECT), even though the modern system had been launched 
almost 10 years earlier in 2004 (Kooreman et al., 2014).  In Indiana 28.2% of physician 
respondents in a survey reported reviewing PDMP data for only 1-10% of their patients 
receiving prescribed controlled substances (Kooreman et al., 2014).  As of June 2014, 
only 20 states had laws mandating that prescribers and in some cases dispensers enroll 
with the PDMP, and 22 states had laws mandating that prescribers and in some cases 
dispensers use the PDMP in certain circumstances (PDMP Center of Excellence, 2014b). 
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1.12.2 LIMITING ACCESS TO MEDICATIONS USED FOR LEGITIMATE USE  
 
 The discussion of PDMP’s ability to reduce supply of certain controlled 
substances is debated as both a positive and negative aspect of the program.  Concerns 
have been raised that PDMPs may have a “chilling effect”, deterring physicians from 
prescribing opioids to successfully treat a patient’s pain, due to the potentially negative 
influence of drug enforcement agents monitoring their prescribing behaviors (Finklea et 
al., 2014).  However, several studies have dispelled these claims, implying that data from 
prescription monitoring programs can be used to reduce the frequency of diversion, 
without threatening legitimate access to prescription drugs (D Baehren et al., 2010; 
Pradel et al., 2009; Reisman et al., 2009).   
 Additionally, given that PDMP data does not include diagnosis information it 
cannot be initially determined without further investigation or availability of the patient’s 
medical records if the individual is or isn’t diverting prescriptions for nonmedical 
purposes.  However, even excessive prescriptions for an individual with a medically 
warranted condition may indicate inappropriate treatment or medical care. 
 Discrepancies in the evaluation of the effectiveness of PDMPs in reducing 
prescription drug abuse may be the result of differences and objectives of different state 
programs.  However, as with any drug abuse policy, the overall goal of PDMPs is to 
achieve a balance between the mitigation of inappropriate use and providing care for 
those individuals with legitimate need for controlled substance prescriptions. 
 
1.13 TEXAS-PRESCRIPTION DRUG ABUSE  
 
 Since 1982 Texas prescribers have been required to use single or multiple 
(triplicate) copy forms, issued by the Department of Public Safety, when writing 
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prescriptions for Schedule II controlled substances.(Texas Department of Public Safety, 
2011)  Believed to be a result of this program, the prescribing of long-acting and high-
dose opioids falls in Texas is below the national average.(Lakey & Lewis, 2014) 
 Drug overdose rates in Texas also fall on the lower spectrum of drug overdose 
rates, as compared to the rest of the United States, with 9.6 deaths per 100,00 people, 
however the number of drug overdose deaths have increased by 78% since 1999 (Trust 
for America's Health, 2013).  Data from Texas poison centers in 2010 has shown a 160% 
increase in opioid analgesic abuse between the years 2000-2010. The most frequently 
reported opioid drug was hydrocodone followed by tramadol, propoxyphene, codeine, 
and oxycodone.  Hydrocodone was involved in 60% of the opioid analgesic abuse cases 
reported to Texas poison centers (Table 1.7).  	  	  	  	  	  	  	  	  	  	  	  	  
	   64	  
Table	  1.7.	  Specific Drugs Involved in Opioid Analgesic Abuse Cases Reported to the 
Texas Poison Center Network During 2000–2010	  
 
Source: Forrester, 2012 
 
 	   Using the Texas poison data, Forrester also revealed variation in abuse rates by 
geographical regions in the state (Figure 1.14) (M. B. Forrester, 2012).  
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Figure 1.14. Opioid-Related Deaths by County 2012 
 
 
 
 
Data Source: Texas Vital Events Death Data Files, Texas Residents 
Prepared by: Texas Department of State Health Services, Center for Health Statistics 
 
 
 
 Abuse rates and substance abuse treatment admissions for prescription painkillers 
are a problem for both the state of Texas and particularly around the metropolitan area of 
Houston (Figure 1.15).  National averages for treatment admission for prescription pain 
killer abuse are 6%, however in Texas they are 7% and 11% in Houston.  Females were 
also more likely (14% vs. 8%) to be admitted for painkiller abuse than males and those 
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identifying as non-hispanic white (18%) (Substance Abuse and Mental Health Services 
Administration, 2010c). 
 
Figure 1.15. Treatment Admissions: Primary Substance of Abuse: United States, 
Texas, and Houston: TEDS 2008 
 
 
Source: Treatment Episode Data Set (TEDS) 2008 
 
 
 The use of opioids nonmedically is most prevalent among 18-25 year olds in 
Texas, which is consistent with national findings (Figure 1.16).  A 2012 survey of Texas 
students in grades 7-12 found that 10.8% reported using codeine cough syrup 
nonmedically at some point in their lives, and 4.0% did so in the past month (Texas 
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Department of State Health Services, 2012.  Prevalence rates for using oxycodone and 
hydrocodone products nonmedically anytime in their lifetime were higher in 2012 (3.6% 
and 7.5%, respectively) than the rates reported in 2008 and 2010 (Texas Department of 
State Health Services, 2012).  In 2013 almost 20% of high	  school	  students	  in	  Texas	  have	  
ever	  taken	  prescription	  pills	  without	  a	  doctor’s	  prescription 
 
 
Figure 1.16. Nonmedical Use of Prescription Pain Relievers 
 
 
Source: Substance Abuse and Mental Health Services Administration, National Survey 
on Drug Use and Health 2013 
 
 
 
1.13.1 DOCTOR SHOPPING IN TEXAS 
 Currently there is very limited research analyzing the prevalence of and factors 
associated with doctor shopping in Texas.  As demonstrated in Figure H, the State of 
Texas falls under the “General Law” of the Uniform Controlled Substances Act of 1970 
pertaining to doctor shopping. Texas does not currently have specific laws pertaining to 
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doctor shopping, however Section 481.129 discussing the offense of fraud states that if  
“A person commits an offense if the person knowingly: possesses, obtains, or attempts to 
possess or obtain a controlled substance or an increased quantity of a controlled 
substance: by misrepresentation, fraud, forgery, deception, or subterfuge.(Centers for 
Disease Control and Prevention National Center for Injury Prevention and Control 
Division of Unintentional Injury Prevention, 2012; Texas Department of State Health 
Services, 1989; The National Alliance for Model State Drug Laws (NAMSDL), 2010) 
 
1.14 PRESCRIPTION ACCESS IN TEXAS 	  
 In 1982 the 67th Texas Legislature created the state’s original prescription drug 
monitoring program, Texas Prescription Program (TPP), under the Department of Public 
Safety, to monitor all Schedule II prescriptions.  The Department of Public Safety is a 
law enforcement agency in Texas.  Texas is one of six states whose PDMP is 
administered by a law enforcement agency (The National Alliance for Model State Drug 
Laws (NAMSDL), 2014).  In 2008 the Texas Legislature expanded the program to 
monitor Schedule II-V controlled substances (National Alliance for Model State Drug 
Laws, 2014a; Texas Department of Public Safety Regulatory Services Division). 
 In 2012 the Regulatory Services Division of the Texas Department of Public 
Safety launched a secure online prescription monitoring program called Prescription 
Access in Texas (PAT) (Texas Department of Public Safety, 2012).  PAT monitors all 
controlled substances Schedule II-IV dispensed in the past 12 months in the state by a 
pharmacy in Texas (Texas Department of Public Safety Regulatory Services Division).  
Dispensing pharmacists are required to report dispensing information to PAT within 
seven days of dispensing.  The users authorized to receive information from PAT are 
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prescribers, pharmacists, physician assistants, law enforcement and judicial/prosecutorial 
officials, and licensing/regulatory boards (National Alliance for Model State Drug Laws, 
2014c).  All registrants are still required by statue to have a current State (DPS) and 
Federal (Green et al.) registration in order to possess, administer, prescribe or dispense 
controlled substances (Texas Department of Public Safety Regulatory Services Division).  
In 2013 PAT collected information on over 49 million prescriptions in the year 2013 
(Texas Department of Public Safety Regulatory Services Division).  To put this into 
perspective, the 2013 Texas Census population was over 26.5 million (Texas Department 
of State Health Services, 2014). 
 Currently there are no training requirements for authorized users before utilizing 
the system and prescribers/dispensers are not mandated to access or enroll in the system.  
PAT utilizes both solicited and unsolicited reporting methods and reports are generated 
for prescribers, pharmacists, law enforcement agencies and licensing agencies (National 
Alliance for Model State Drug Laws, 2014b).  Unsolicited reports are currently provided 
to prescribers, pharmacists, law enforcement, and licensing boards.  PAT allows for 
interstate sharing with authorized users in other states (National Alliance for Model State 
Drug Laws, 2014c) 	  
1.15 SUMMARY 
 
 After extensive review of the current literature, it can be concluded that 
prescription drug abuse is a vast problem affecting not only the State of Texas but 
individuals across the U.S..  Further research is currently needed to examine the current 
state of controlled substance prescription utilization and the prevalence of indicators of 
abuse, particularly in Texas. 
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MANUSCRIPT 1 
 
Using Prescription Drug Monitoring Program Data to Identify Aberrant 
Prescription Drug Use Behaviors  
 
Background 
 
Challenges in Defining Abuse 
 
 Prescription drug abuse is a perilous public health problem that has resulted in an 
excess of deaths, emergency room visits and millions of healthcare dollars consumed 
(Birnbaum et al., 2011; Centers for Disease Control and Prevention, 2014d; Hansen et al., 
2011; National Institute on Drug Abuse, 2011d).  According to the Centers for Disease 
Control and Prevention (CDC), each day nearly 7,000 people are treated in emergency 
departments (ED) for the nonmedical use of prescription opioids (Centers for Disease 
Control and Prevention, 2015).  Overdose deaths involving opioids have exceeded deaths 
involving all illicit drugs (e.g., heroin, cocaine) combined (Centers for Disease Control 
and Prevention, 2013c; LJ Paulozzi et al., 2011).  Prescription drug abuse is a complex 
and multi-faceted problem, occurring as the result of both legitimate (e.g., originating 
from prescribers, dispensed by pharmacies) and illegitimate means (e.g., illegitimate 
internet pharmacies, theft) (American College of Preventive Medicine, 2011).  While 
controlled substance prescriptions (CSPs) obtained by illicit use is a huge problem, in the 
US it has been found that most prescriptions used for nonmedical means originate from 
prescribers (Manchikanti, Abdi, et al., 2012; Substance Abuse and Mental Health 
Services Administration, 2011a).  Research attributing the recent rise in incident heroin 
abuse cases to individuals with previous opioid dependence has escaladed the necessity 
of addressing this  problem.  Studies have reported that almost 80% of new heroin users 
had previous utilized opioids for nonmedical purposes (Muhuri et al., 2013). 
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Consequently, efforts to identify and address prescription drug abuse are needed now 
more than ever.   
  There are numerous factors which contribute to prescription drug abuse.  One 
major challenge to addressing this epidemic is interpreting the enigmatic definition of 
abuse.  Both the National Institute on Drug Abuse (NIDA) and the Substance Abuse and 
Mental Health Services Administration (SAMHSA) define prescription drug abuse as 
using a medication without a prescription, in a way other than as prescribed, or for the 
experience or feelings elicited (National Institute on Drug Abuse, 2014c; Substance 
Abuse and Mental Health Services Administration Center for Behavioral Health Statistics 
and Quality, 2013a).  However, translating this definition into daily clinical practice can 
be confusing and often difficult for healthcare providers to interpret.  
  The discord of identifying prescription drug abuse in individual patients has 
conceivably manifested out of the epidemic proportions of heterogeneous individuals 
abusing or misusing prescription medications (Ohio Prescription Drug Abuse Task Force, 
2010; Substance Abuse and Mental Health Services Administration, 2014b).  Drug abuse 
is no longer limited solely to individuals who have a stereotypical drug abuser profile.  
Prescription drug abuse spans across age groups, gender, and socioeconomic status 
(Buurma et al., 2008; Centers for Disease Control and Prevention, 2013a; Hall et al., 
2008; Han et al., 2012; Substance Abuse and Mental Health Services Administration, 
2014a; White et al., 2009).  In the past, abuse of illicit drugs had been highly associated 
with males (Substance Abuse and Mental Health Services Administration, 2014a).  
However, among prescription opioid abusers, the propensity for abuse between genders 
has varied greatly across studies and is no longer specific to males (Buurma et al., 2008; 
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Hall et al., 2008; Han et al., 2012; White et al., 2009).  In fact, the rate at which women 
have died as a result of opioid overdoses increased 400% from 1999 to 2010 for women 
compared to 265% for males during the same time period (Centers for Disease Control 
and Prevention, 2013a; Substance Abuse and Mental Health Services Administration, 
2014a).  While illicit drug abuse is most common among young adults (e.g., 18-35 years 
old), studies on prescription drug abuse have reported indicators spanning across all 
different age categories and patient characteristics (Buurma et al., 2008; Centers for 
Disease Control and Prevention, 2012; Fishman, 2010; Simeone et al., 2006; Substance 
Abuse and Mental Health Services Administration, 2010b; Wilsey et al., 2010).  
Moreover, the relatively vast indicators for prescription drug abuse are often difficult to 
conceptualize and quantify in research and practice.  Therefore, epidemiological studies 
focused on issues of pain management and opioid use would benefit from establishing 
consistent criteria for indicators of abuse (Astho, 2014).   
  
Use of Databases to Identify Abuse 
 A large number of prior studies which examined prescription drug abuse trends, 
have utilized insurance prescription and medical claims databases.  However, study 
limitations may underestimate the prevalence of prescription drug abuse.  For example, 
claims databases often have limited generalizability given they only capture patients 
covered by insurance (Crystal, Akincigil, Bilder, & Walkup, 2007).  Cash payment (i.e., 
no third party payment) of CSPs, especially opioids, has been shown to be significantly 
correlated with prescription drug abuse and misuse (M. S. Cepeda, D. Fife, W. Chow, G. 
Mastrogiovanni, & S. C. Henderson, 2013; McDonald & Carlson, 2013).  Given this 
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limitation, claims data often produces biased estimates of both the prevalence and risk 
factors for prescription drug abuse.  Not to mention claims databases are not utilized or 
available in daily clinical practice for prescribers and pharmacists.  Additionally, claims 
databases can be very costly to obtain for research purposes. 
 Conversely, one tool that has the potential to change the way researchers, 
prescribers and pharmacists identify prescription drug abuse is state operated prescription 
drug monitoring programs (PDMPs).  PDMPs are electronic databases which collect 
specific data on CSPs dispensed within the respective state.  Currently, 49 states have an 
operational PMDP (U.S. Department of Justice Drug Enforcement Administration Office 
of Diversion Control, 2011).  The specific data that PDMPs collect vary by state, 
however most databases contain the patient’s name, age, address, information on their 
CSP utilization and specific information about each dispensed prescription (drug name, 
national drug code (NDC), quantity dispensed), prescription fill dates, information of the 
prescriber and pharmacy dispensing each CSP (National Alliance for Model State Drug 
Laws, 2014d).  Unlike other large claims databases, PDMP databases capture all 
outpatient CSPs dispensed regardless of payment type used to purchase the prescription 
(e.g., insurance, cash) (Clark et al., 2012).  CSP data is provided only to authorized users 
(dictated by state statue) by the individual program, such as prescribers, pharmacists and 
often times law enforcement.  Additionally, some PDMPs also provide data for research 
purposes.  PDMP data can be used within daily clinical practice and for research 
purposes allowing for both individual patient’s CSP utilization history to be examined 
and to examine utilization patterns and prescribing practices (The PDMP Training and 
Technical Assistance Center, 2014).   
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Utility of PDMP Data  
Clinical Utilization 
 The extant literature has illustrated that data acquired via PDMPs have the 
capability to improve clinical decision-making, reduce excessive CSP prescribing, and 
decrease prescription drug abuse and doctor shopping (Haffajee et al., 2015; PDMP 
Center of Excellence, 2014a; Simeone et al., 2006; U.S. General Accounting Office, 
2002; United States General Accounting Office, 2002).  PDMP data can be a powerful 
clinical tool, as study results have reported changes in provider prescribing behavior and 
reduced opioid consumption after implementation of this program (DF Baehren et al., 
2010; Feldman et al., 2012; Morgan, Weaver, Sayeed, & Orr, 2013; Thomas et al., 2014). 
Thomas et al. (2014) found that among prescribers in Massachusetts who reviewed their 
patient’s PDMP data, 78.5% took further action, such as adding the prescription history 
to the patient’s file, discussing the report with other prescribers and discussing the report 
with the patient (Thomas et al., 2014).  The same study found that upon reviewing PDMP 
data, only 8.4% of prescribers were aware of most of the other prescribers that were listed 
on the individual patient’s report (Thomas et al., 2014).  Baehren et al. also reported that 
within their prospective study, physicians who reviewed patient PDMP data prescribed 
61% fewer opioids than originally planned.(D Baehren et al., 2010) 
  
State PDMP: Program Utility 
 Currently available in 38 state PDMPs is the generation of unsolicited or 
proactive reports based on PDMP data.  This data can specifically be utilized by state 
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programs to identify the aforementioned aberrant behaviors.  PDMPs with this feature 
have the capability to generate proactive or unsolicited reports for prescribers and 
pharmacists based on PDMP data that may suggest aberrant behavior (PDMP Center of 
Excellence, 2014c).  PDMP reports use predetermined criteria established by the specific 
program to identify at-risk patients or questionable activity based on their CSP utilization 
(e.g., utilizing ≥5 prescribers and ≥5 pharmacies in 12 months) (PDMP Center of 
Excellence, 2014c).   Simoene and Holland reported that state PDMPs which are 
proactive in their reporting were effective in reducing the per capita supply of opioids and 
stimulants, as compared to states without this feature (Simeone et al., 2006).  
 
Research Purposes: PDMP Data as a Public Health Tool 
 Establishing an evidence-based consensus on well-known aberrant behaviors 
associated with abuse can also help local public health authorities and researchers 
accurately define the populations most at risk for prescription drug abuse.  More 
importantly, better understanding of at risk populations would lead to more efficient 
allocation of resources related to prescription drug abuse prevention and treatment.  
 
Indicators of Aberrant Behavior 
 
 There are several aberrant behaviors that suggest CSP misuse or abuse that are 
readily identifiable by reviewing PDMP data.  Aberrant behavior can be defined as 
patient behaviors that may indicate prescription medication abuse or behaviors that are 
more likely to be associated with misuse/abuse (National Institute on Drug Abuse).  This 
paper aims to highlight aberrant CSP behavior which can be identifiable through PDMP 
data.  Three aberrant behaviors discussed in this paper include: receiving inappropriate 
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and/or overlapping combinations of CSPs; utilizing multiple providers (i.e., doctor 
shopping) to obtain prescription opioids and other CSPs; and receiving a high daily 
morphine equivalents dose (MED).   
 
Multiple Provider Episodes (MPEs) 
 Individuals who obtain prescriptions for the same CSPs from multiple prescribers 
without the prescribers’ knowledge of the other prescriptions are often referred to as 
doctor shoppers, pharmacy shoppers, or as having a multiple provider episode (Centers 
for Disease Control and Prevention National Center for Injury Prevention and Control 
Division of Unintentional Injury Prevention, 2012; McDonald & Carlson, 2013; Sansone 
& Sansone, 2012).  While only a relatively small proportion of patients are representative 
of this behavior, moreover, they represent a significant contribution to diversion rates and 
fill a disproportionately large number of CSPs (Cepeda, Fife, Berwaerts, Yuan, & 
Mastrogiovanni, 2014; M. Cepeda, D. Fife, Y. Yuan, et al., 2013).  Additionally, the 
Department of Justice reported that shopping behavior is the primary method used to 
obtain opioids for illegitimate means (U.S. Government Accountability Office, 2011).  
 Studies analyzing patients who utilize multiple providers to obtain CSPs (e.g., 
opioids) have varied regarding their operational definitions and indicators of aberrant 
behavior.  Various classifications are based on the numbers of pharmacies visited; 
numbers of prescribers used; prescriptions that are overlapping; using more than one 
class of CSP from different providers; early refills of prescriptions; and excess doses over 
different periods of time (Buurma et al., 2008; Cepeda et al., 2014; M. Cepeda, D. Fife, 
Y. Yuan, et al., 2013; AM Gilson et al., 2012; Hall et al., 2008; Katz et al., 2010; Peirce 
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et al., 2012; Wilsey et al., 2010; Yang et al., 2015).  Given that prescribers and 
pharmacists may not be aware of all the CSPs that patients have filled or the number of 
other prescribers and pharmacies filling other prescriptions, PDMP data can assist 
providers by providing a summary of the patient’s CSP history.  
 
Simultaneous or Overlapping Prescriptions 
 A second aberrant behavior identifiable with PDMP data is patients receiving 
overlapping prescriptions for CSPs.  Patients receiving overlapping prescriptions for 
CSPs have an increased risk for not only MPEs, but also for overdose deaths and serious 
adverse events (M.B Forrester, 2011; Liu, Logan, Paulozzi, Zhang, & Jones, 2013; U.S. 
Department of Health and Human Services, 2013; Wunsch, Nakamoto, Behonick, & 
Massello, 2009).  One combination of CSPs popular among abusers is the concomitant 
use of opioids, muscle relaxants and benzodiazepines, due to the euphoric sensation or 
high that the combinations produce and also for their high street value (M.B Forrester, 
2011; U.S. Drug Enforcement Administration, 2013b).  While the literature reveals little 
medical justification for this combination, studies have found a high prevalence of this 
inappropriate combination (M.B Forrester, 2011; Liu et al., 2013; Olsen, 2010; Volkow, 
2014).  Additionally, in 2009 the majority of prescription drug-related ED visits were 
attributed to opioids alone and in combination with benzodiazepines (Substance Abuse 
and Mental Health Services Administration, 2010b). 
 As can be expected, the aberrant behaviors discussed in this paper have been 
found to be highly correlated.  Wilsey et al. reported that the greatest predictor of having 
a MPE was simultaneously receiving prescriptions for different CSPs (Wilsey et al., 
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2010).  This study found that individuals who were prescribed simultaneous prescriptions 
for stimulants/anorectics, benzodiazepines and opioids had a 25.1 times increased odds of 
having an MPE (Odds Ratio [OR])=25.10, 95% Confidence Interval [CI]=22.73-27.72) 
(Wilsey et al., 2010).  While simultaneously using CSPs has dire consequences, there are 
few clinical guidelines regarding overlapping CSP use and which specific combinations 
should be avoided.  
 PDMP data can help to identify individuals with overlapping and medically 
unnecessary prescriptions for controlled substances.  This practice can not only assist 
with identification of aberrant CSP use, but also harmful drug-drug interactions which 
could lead to an adverse event or even death. 
 
High Daily Morphine Equivalent Dosage 
 One of the gold standards for comparing doses across different opioids is by 
measuring the daily morphine equivalent dose (MED) (Boudreau et al., 2009; AM Gilson 
et al., 2013; Manchikanti, Abdi, et al., 2012; Prescription Drug Monitoring Program 
Training and Technical Assistance Center, 2013).  Daily dosage among chronic users of 
opioids has been found to increase with continued use over time (Cepeda et al., 2010; LJ 
Paulozzi, Zhang, Jones, & Mack, 2014).  These findings suggest that chronic opioid users 
experience tolerance to their opioids and require higher daily MED.  Guidelines vary 
concerning threshold levels for daily MED in patients with nonmalignant pain, however 
several official guidelines, including The Agency for Healthcare Research and Quality 
and the Washington State Opioid Guidelines, recommend using caution when the average 
daily MED doses exceed 120 mg (National Guideline Clearinghouse (NGC)),(Agency 
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Medical Directors Group, 2010; Group Health Cooperative, 2014).  Opioid overdoses 
have also been found to be highly correlated with a high average daily opioid dose (LJ 
Paulozzi et al., 2012).  Bohnert et al. and Dunn et al. found that patients receiving >100 
mg/day had an exponential increase in the risk of overdose death and accounted for 
approximately 40% of opioid overdoses (Bohnert et al., 2011; Dunn et al., 2010).  Dunn 
et al., also found that as compared to patients receiving an average daily opioid dose of 1-
20 mg per day, those receiving 100mg or more per day had an 8.9 fold increase in 
overdose risk and a 1.8% annual overdose rate (Dunn et al., 2010).  Moreover, research 
has found that even doses as low as 40 or 50 mg of daily MEDs may be responsible for a 
large number of ED admissions (Manchikanti, Abdi, et al., 2012). 
 PDMP data can be used to identify individuals with dangerous levels of daily 
MED or with rapid dose escalation.  This data can also help prescribers identify 
individuals who may not be responding to opioids even at high dosage levels, who may 
benefit from an alternative pain therapy.  Additionally, patients identified as highly 
dependent on opioids may indicate the presence of a comorbid mental health disorder 
(National Institute on Drug Abuse, 2011c). Patients on high dose opioids have been 
found to have higher rates of mental health problems (Kobus et al., 2012; Merrill et al., 
2012; Seal et al., 2012).  
 
Discussion 
PDMP Utilization and Mandates 
 A prerequisite to the potential positive effects of PDMP data and unsolicited 
reporting is increasing utilization of these databases.  Unfortunately, due to factors such 
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as limited resources, unawareness of the programs and legislative policies, PDMPs are 
not currently being utilized to their full potential (PDMP Center of Excellence, 2014c).  
Currently, only 22 PDMPs mandate prescribers to use the system in certain 
circumstances before prescribing CSPs (Haffajee et al., 2015).  In Ohio Baehren et al. 
found that a large portion of prescribers reported reviewing PDMP data for only 1-10% 
of their patients receiving prescribed CSPs (DF Baehren et al., 2010).  In states where 
PDMP use is not mandated, estimates of prescriber registration with their respective 
PDMP is approximately 35% (Kreiner, Nikitin, & Shields, 2014).  Other research has 
indicated a high lack of awareness of PDMPs among nonusers (ML  Fleming, Hatfield, 
Wattana, & Todd, 2014). 
 While the Centers for Disease Control and Prevention, The PDMP Center of 
Excellence and the National Alliance for Model State Drug Laws recommend sending 
unsolicited reports to end users as a best practice, of the 45 states that have the capability 
to send unsolicited reports, only 53% of the programs were utilizing this practice 
(National Alliance for Model State Drug Laws, 2012; PDMP Center of Excellence, 
2014c). Additionally, as of 2014, only 19 states were sending unsolicited reports to all 
authorized users (e.g., prescribers, pharmacists, law enforcement and licensing entities) 
(National Alliance for Model State Drug Laws, 2014e).  However, the inclusion of 
unsolicited reports could assist in CSP prescribing practices, taking the guess work out of 
identifying aberrant CSP utilization behaviors and function as a valuable clinical tool in a 
busy healthcare or pharmacy practice.  
 
Limitations of PDMP Data   
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 One major disadvantage of using PDMP data for identifying aberrant behavior is 
their lack of patient clinical data.  While establishing validated criteria for identifying 
aberrant CPS use is the first step to addressing this problem, dispensing and utilization 
data cannot definitively confirm abuse.  Prescribers and pharmacists should follow up 
with patient medical records for verification of medically warranted use.  Therefore, 
PDMP data needs to be integrated with electronic health records (EHRs) to properly 
identify the patient’s medically justified or aberrant CSP use.  
 
Future Direction 
 Moving forward, future research is needed to examine the effectiveness of 
PDMPs regarding identifying individuals with aberrant behaviors, such as receiving 
overlapping combinations of CSPs, utilizing multiple providers to obtain CSPs, and 
consuming a high daily MED.   
 
Conclusions 
 
 PDMPs are a powerful clinical and public health surveillance tool that can be 
used to identify aberrant CSP behaviors among individuals and populations.  Proactively 
using PDMP data and unsolicited reporting provides prescribers and pharmacists an 
opportunity to educate patients on their CSP utilization and intervene when appropriate.  
Utilizing PMDPs to their full potential will be essential to addressing the current 
prescription drug abuse epidemic. 
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MANUSCRIPT 2 
 
Prevalence and Factors Associated with Patients Receiving Potentially 
Inappropriate Overlapping Controlled Substance Prescriptions 
 
 
Abstract 
Introduction: Controlled substance prescription (CSP) use and abuse in the U.S. has 
reached unprecedented levels.  One common method of abuse is the use of overlapping or 
concomitant use of certain CSPs. 
Methods: This was a retrospective, cohort analysis of data from the 2013-2014 Texas 
Prescription Drug Monitoring Program Database (PDMP).  Logistic regression analysis 
was employed to examine the patient-level and prescription utilization factors associated 
with patients utilizing overlapping CSPs. 
Results: Among all Texas patients utilizing CSPs, 1,660,015 patients (15.99%) had at 
least one episode of utilizing one of the five overlapping CSPs combinations discussed in 
this manuscript. Overlapping opioid prescriptions were found to be the most prevalent 
combination among Texas patients (17.23%, n=1,574,572).  Utilization of opioids, being   
≥18 years of age, utilizing CSPs for >30 days, utilizing greater than one CSP, having a 
multiple provider episode, and traveling >25 miles to obtain CSPs were all statistically 
significant predictors of utilizing overlapping CSPs. 
Conclusion:  This study found a high prevalence of patients utilizing overlapping CSPs.  
This practice is concerning for patient safety and public health in Texas.  Programs such 
as the Texas Prescription Drug Monitoring Program should be utilized to address 
prescription drug abuse behaviors, such as utilization of overlapping CSPs.  
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Introduction 
 Controlled substance prescriptions (CSPs) have become a fundamental in the US 
healthcare system, with over 259 prescriptions written for opioid prescriptions alone in 
2012 (Centers for Disease Control and Prevention).  Classified based on their high 
potential for dependence, the abuse and misuse of CSPs, such as opioids and 
benzodiazepines, contributes significantly to morbidity and mortality rates in the US 
(U.S. Department of Health and Human Services, 2013; U.S. Department of Justice Drug 
Enforcement Administration Office of Diversion Control, 2014).  While the increased 
availability and consumption of these prescription medications has contributed to 
elevated overdose rates and adverse events, there are several aberrant CSP utilization 
behaviors that responsible for a disproportionate percentage of these statistics and also 
may indicate abuse (Volkow, 2014).  One such behavior is the concomitant use of 
different or the same controlled substance prescriptions.  Concurrent or overlapping use 
of CSPs can be dangerous, resulting in unintended adverse events (AEs) or overdose 
deaths (Dunn et al., 2010; Hall et al., 2008; Wunsch et al., 2009).   
 According to the Substance Abuse and Mental Health Services Administration 
(SAMHSA) and the Drug Abuse Warning Network (DAWN), the use of prescription 
opioids alone and in combination with other CSPs is responsible for half of the 1.2 
million ER visits associated with the nonmedical use of pharmaceuticals (Substance 
Abuse and Mental Health Services Administration, 2012a).  A 2015 study from Jones and 
McAninch found an almost three times increase in drug overdose deaths from 2004 to 
2011 from overlapping use of opioids and benzodiazepines (Jones & McAninch, 2015).  
A nationwide study from Calcaterra et al. also reported that the concurrent use of opioids 
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and benzodiazepines was the most common cause of multi-drug overdose death 
(Calcaterra, Glanz, & Binswanger, 2013). 
 The most common practice of concomitant use related to or associated with CSPs 
are patients taking two or more overlapping opioids (Express Scripts, 2014).  A 2013 
study from Express Scripts found that almost 60% of patients utilizing opioids were 
taking a combination of prescription drugs that are associated with serious safety risks 
and adverse events (e.g., cardiovascular risks). The majority of these patients were taking 
either benzodiazepines, muscle relaxants or both with their opioids and were largely 
female (62.3%) (Express Scripts, 2014). 
 Overlapping prescriptions, especially for opioids, have been shown in previous 
studies as having a strong association with other indicators of prescription drug abuse, 
such as doctor shopping, the utilization of a high daily dosage (e.g. >100mg/day), and 
long-term use of CSPs (Bohnert et al., 2011; M. Cepeda, D. Fife, W. Chow, G. 
Mastrogiovanni, & S. Henderson, 2013; Dunn et al., 2010; Express Scripts, 2014; White 
et al., 2009; Wilsey et al., 2010).  Wilsey et al. found that individuals who had received 
stimulants and benzodiazepines concurrently had a 20 times increased odds of having a 
multiple provider episode (MPE), also known as doctor shopping (Wilsey et al., 2010).  
Utilizing overlapping opioids increases a patient’s daily morphine equivalent dose 
(MED) (calculated to convert opioid dose to standard dose based on type and quantity of 
opioid dispensed) (PDMP Training and Technical Assistance Center, 2013b). This 
practice is especially concerning given that previous research reported that patients 
receiving 100 mg of opioids or more per day had an 8.9 fold increase in overdose risk, as 
compared to receiving 1-20 mg per day (Dunn et al., 2010).  Additionally, while the 
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utilization of overlapping prescriptions is often the result of inappropriate prescribing, 
certain combinations of CSPs are also obtained aberrantly by patients due to the heroin 
like effect they produce when taken concurrently, and also for their high street value 
(M.B Forrester, 2011; U.S. Drug Enforcement Administration, 2013a). 
 This study aimed to identify the prevalence and factors associated with patients 
receiving inappropriate overlapping CSPs in the State of Texas.  Texas, specifically the 
Houston area, is a national hotspot for patients consuming the deadly combination of 
opioids, benzodiazepines and muscle relaxants, also known as the Triple Cocktail (M.B 
Forrester, 2011; Horswell, 2010; Olsen, 2010). 
 
Methods 
Design 
 This was a retrospective, cohort analysis using data from the Texas Prescription 
Drug Monitoring Program Database (PDMP).  The Texas PDMP database is operated by 
the Texas Department of Public Safety (DPS).  The researchers obtained deidentified data 
based on all CSPs dispensed from outpatient pharmacies in the State of Texas.  This 
study included prescriptions dispensed from June 1, 2013 to June 1, 2014, which was 
comprised of 38,350,287 CSPs consumed by 10,381,532 unique patients (Texas 
Department of Public Safety Regulatory Services Division).     
 
Dependent Variable 
 The binary (0/1) dependent variable was the presence of receiving at least one 
inappropriate combination of CSPs.  The following three combinations were included as 
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the dependent variable in a logistic regression analysis: 1) overlapping opioid 
prescriptions; 2) overlapping opioid, stimulant, and benzodiazepine prescriptions; 3) 
overlapping opioid, muscle relaxant, and benzodiazepine prescriptions (Triple Cocktail). 
 
Independent Variables 
 The patient-level variables included: patient age category; the number of CSPs 
utilized in the 12-month study period; the duration of CSP utilization (total days of use); 
daily MED (for opioid prescriptions); the distance between the patient’s zip code and 
CSP prescriber’s zip code; the distance between the patient’s zip code and the filling 
pharmacy’s zip code; and the distance between the prescriber’s zip code and the filling 
pharmacy’s zip code; MPE (defined as utilizing ≥5 prescribers and 5≥ pharmacies in 12-
month period). 
 
Statistical Analysis 
 The prevalence of patients receiving overlapping CSPs was conducted among the 
entire cohort of CSP utilization patients residing in Texas and among the cohort of 
patients with a MPE.  The prevalence of the following combinations was identified: 1) 
overlapping opioid, muscle relaxant, and benzodiazepine prescriptions (Triple Cocktail); 
2) overlapping opioid and benzodiazepine prescriptions; 3) overlapping opioid, stimulant, 
and benzodiazepine prescriptions; 4) overlapping stimulant and benzodiazepine 
prescriptions; and 5) overlapping opioid prescriptions.  Overlapping use was defined as 
having prescriptions with ≥7 days of overlap (Liu et al., 2013).  Overlapping opioid 
prescriptions were further analyzed by opioid type: long-acting/extended release and 
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short-acting/immediate release.  Descriptive statistics were conducted on the main CSP 
utilization cohort and among the cohort of CSP utilization patients with one of the five 
potentially inappropriate overlapping CSPs. 
 The association between individual-level variables and the utilization of an 
inappropriate combination of CSPs were examined using logistic regression modeling.  
This study and its research activities were approved by The Institutional Review Board at 
the University of Houston. 
 
Results 
 Among all Texas patients utilizing CSPs there were 1,660,015 patients (15.99%) 
with at least one episode of utilizing one of the five overlapping CSPs combinations.  
Within the MPE cohort, 17,878 patients (93.00%) had at least one overlapping use 
episode.  While 17.23% (n=1,574,572) of all Texas patients utilizing CSPs had at least 
one episode of overlapping opioid prescriptions, alarmingly so did 90.78% (n=17,450) of 
patients in the MPE cohort (Table 2.1). The vast majority (95.17%) of overlapping opioid 
prescriptions were for two short-acting opioids (e.g., hydrocodone combination products) 
(Table 2.2).  Within the MPE cohort, overlapping use of opioids and benzodiazepines and 
stimulants and benzodiazepines was prevalent, 12.23% and 11.57%, respectively. 
 Patients in both the main cohort and the overlapping use cohort were mostly 
between the ages of 18-64 (Table 2.3).  A much higher percentage of patients in the 
overlapping use cohort had a higher daily MED, with 7.43% of the patients utilizing ≥100 
mg per day, compared with only 2.34% of patients in the main cohort.  Patients with 
overlapping CSP use also consumed a higher mean number of CSPs during the 12 
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months of analysis (M±SD, 9.40 ± 9.61 vs. 3.62 ± 5.42, respectively) and for a longer 
duration (>150 days, 33.85% vs. 12.49%, respectively).  A larger proportion of patients 
in the CSP overlapping use cohort also had at least one MPE during the study analysis 
(1.08% vs. 0.18%). 
Logistic Regression 
  Among the CSP overlap cohort, 1,581,274 (95.25%) patients had at least one of 
the three inappropriate combinations used in the logistic analysis (Table 2.4).  All 
patients over the age of 18 had an increased odds of having an overlapping CSP, as 
compared to those under the age of 18.  A strong association was found between utilizing 
opioids and having overlapping CSPs, especially for those patients using an average 
MED of  >100 mg per day (adjusted odds ratio [OR]=140.44 [95% CI: 139.65-141.23]).  
The distance between the patient’s zip code and the CSP prescriber’s zip code and filling 
pharmacy’s zip code were not significant predictors of utilizing overlapping CSPs.  
Having a MPE increased the patient’s odds of using overlapping CSPs by two and half 
times (OR= 2.55 [ 95% CI: 2.51-2.58]).  The model was a strong predictor of patient’s 
receiving inappropriate combinations of CSPs, with a c-score of 0.91. 
 
Discussion 
 In this study the prevalence of patients receiving prescriptions for inappropriate 
combinations of CSPs, especially overlapping opioids, was alarming given the lack of 
clinical evidence for their concomitant use and their strong association with AEs. The 
prevalence of overlapping opioids was driven almost completely by patients obtaining 
overlapping prescriptions for two short-acting opioids, which was comprised mostly of 
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prescriptions for short-acting hydrocodone.  Thus this overlapping opioid phenomenon 
was not driven by patients requiring a long-acting opioid with a short-acting opioid for 
breakthrough pain, which is often justified in the management of severe chronic pain 
(Argoff & Viscusi, 2014).  Short-acting opioids are more frequently prescribed in 
emergency room settings and hydrocodone specifically has been found to be the most 
commonly abused opioid (Drug Enforcement Administration; Nawar, Niska, & Xu, 
2007).  Long-acting opioids however, are less frequently prescribed and generally 
reserved for use when other treatment options have failed (U.S. Food and Drug 
Administration, 2013).  Nevertheless, regardless of the opioid’s formulation, the results 
of the daily MED in the logistic model revealed that using any type of opioid increased a 
patient’s odds of utilizing overlapping CSPs drastically.   
 While this study did not capture a large number of demographic characteristics, 
the relatively evenly distributed association between patient age category and utilization 
of overlapping CSPs demonstrates the vast nature of aberrant CSP utilization behavior.  
This finding highlights the challenge of targeting drug abuse prevention efforts to a 
specific demographic or age category and the immense nature of this epidemic. 
 Given the high prevalence of patients with an MPE who also utilized overlapping 
CSPs and the sizeable association found between the two variables, this may indicate that 
patients with an MPE are doctor shopping for CSPs with intention to take them 
concurrently.  This hypothesis has also been supported by the findings of Wilsey et al.. 
(Wilsey et al., 2010).  Therefore, when doctor shopping is suspected, prescribers should 
also examine the patient’s CSP fill history, corresponding dates, and vise versa. 
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 There are currently programs and polices in place to help detect aberrant CSP use 
and indicators of abuse prior to issuing prescriptions for pain management.  One such 
program is the Texas Prescription Drug Monitoring Program (PDMP), which is a 
statewide program that collects data on all CSPs dispensed within the state (U.S. 
Department of Justice Drug Enforcement Administration Office of Diversion Control, 
2011).  Prescribers and pharmacists can review a patient’s CSP dispensing history within 
the PDMP to determine if a patient has inappropriate and/or overlapping CSP use (PDMP 
Center of Excellence, 2014a).  This program can also help prescribers prevent future AEs 
and even facilitate an intervention regarding the patient’s aberrant CSP utilization when 
needed. 
 As aforementioned the greatest limitation of this study is the lack of patient 
demographic and clinical data available in the database.  However, given that several of 
the predictors were significantly associated with overlapping CSP use, CSP utilization 
behavior can be sufficiently used to identify aberrant behavior. 
  
Conclusion 
 Polypharmacy of CSPs is a dangerous practice, which should be avoided when 
not medically necessary.  Given the high prevalence of Texas patients utilizing 
overlapping CSPs, this could result in very serious implications for patient health 
outcomes.  Through the implementation of policies and programs, such as state PDMPS, 
patients with aberrant CSP utilization behaviors, such as utilizing overlapping CSPS, can 
be identified and future adverse events can be avoided. 
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Tables 
 
Table 2.1 Prevalence of Potentially Inappropriate Overlapping1 Controlled 
Substance Prescription Utilization 
Overlapping 
Combination 
All CSP2 Utilization 
Patients 
(10,381,532) 
MPE3 Cohort 
(19,223) 
 Frequency4 Percent  Frequency4 Percent  
Opioids, benzodiazepines, 
muscle relaxants5 7,077 0.07 290 1.51 
Opioids and 
benzodiazepines 73,266 0.71 2,351 12.23 
Opioids, benzodiazepines, 
stimulants5 25,178 0.24 1,563 8.13 
Stimulants and 
benzodiazepines 108,346 1.04 2,224 11.57 
Overlapping opioid use5 1,574,572 17.23 17,450 90.78 
1Overlapping defined as ≥7 days of concurrent use 
2Controlled Substance Prescription 
3MPE: Patients utilizing ≥5 prescribers and 5≥ pharmacies in 12-month period 
4Frequencies not mutually exclusive 
5Overlapping combinations used in final logistic model 
 
Table 2.2 Prevalence of Overlapping Opioids by Opioid Type 
Overlapping Combination Overlapping Opioid Use Patients (1,574,572) 
 
Frequency Percent 
1 Short-Acting + 1 Long-Acting Opioid 
Overlap 447 0.03 
2 Long-Acting Opioids Overlap 75,572 4.80 
2 Short-Acting Opioids Overlap 1,498,553 95.17 
1Overlapping defined as ≥7 days of concurrent use 
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Table 2.3 Descriptive Statistics of All Patients Utilizing CSP1 in Texas  
and Among Overlapping CSP Use Cohort 
  All CSP Utilization in Texas (10,381,532) 
Any Overlapping 
Use2 Cohort 
(1,660,015)3 
Variable  Frequency Percent Frequency Percent 
Age Distribution 
<18 927,144 8.93 24,484 1.47 
18-34 2,248,759 21.66 261,278 15.74 
35-44 1,619,562 15.60 250,379 15.08 
45-64 3,528,745 33.99 698,688 42.03 
65-74 1,139,414 10.98 238,137 14.35 
≥75 917,908 8.84 188,049 11.33 
Average Daily 
Morphine 
Equivalent 
(MED) 
0 5,163,761 49.74 145,600 8.77 
1-19mg 1,519,756 14.64 399,502 24.07 
20-49 2,621,524 25.25 759,049 45.73 
50-99 833,655 8.03 232,332 14.00 
≥100 242,484 2.34 123,262 7.43 
Number of 
Controlled 
Substance 
Prescriptions 
(mean) 
 3.62 ± 5.42 9.40 ± 9.61 
Total Days with 
CSP (during 365 
days of analysis) 
1-30 4,849,813 46.72 366,456 22.08 
31-60 2,904,381 27.98 380,630 22.93 
61-90 627,818 6.05 153,538 9.25 
91-149 703,287 6.77 197,722 11.91 
>150 1,296,233 12.49 561,669 33.84 
Distance Between 
Patient Zip and 
Prescriber Zip 
(mean in miles) 
 25.59 ± 119.07 27.78 ± 106.50 
Distance Between 
Patient Zip and 
Pharmacy Zip 
(mean in miles) 
 30.56  ± 142.91 25.51 ± 131.05 
Distance Between 
Prescriber and 
Pharmacy 
(mean in miles) 
 44.46 ± 178.92 40 ± 163.37 
Multiple Provider 
Episode (MPE)  19,223 0.18 17,878 1.08 
1Controlled Substance Prescription 
2Overlapping defined as ≥7 days of concurrent use 
3Numbers may not add up to 1,660,015 due to missing values 
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Table 2.4 Patient Factors Associated with Use of 
Overlapping Controlled Substance Prescriptions 
Patient-Level Variables 
 Variable Odds Ratio 95% C.I.1 
Age category 
(<18 reference) 
18-34 2.36 2.34-2.38 
35-44 2.60 2.58-2.63 
45-64 2.97 2.95-3.00 
65-74 3.22 3.19-3.25 
>75 3.15 3.12-3.18 
Distance Between Patient Zip and 
Prescriber Zip 
(1-25 miles reference) 
26-99 miles 1.15 1.14-1.6 
>=100 1.07 1.06-1.08 
Distance Between Patient Zip and 
Pharmacy Zip 
(1-25 miles reference) 
26-99 miles 0.96 0.95-0.97 
>=100 0.93 0.92-0.94 
Distance Between Prescriber and 
Pharmacy 
(1-25 miles reference) 
26-99 miles 1.01 1.01-1.02 
>=100 0.94 0.93-0.95 
Number of CSPs2 continuous 1.11 1.10-1.12 
Daily Morphine Equivalent 
(0 mg reference) 
1-19mg 65.76 65.50-66.03 
20-49mg 71.19 70.92-71.46 
50-99mg 70.91 70.60-71.22 
>100mg 140.44 139.65-141.23 
Total Study Days with CSPs 
(<30 reference) 
31-60 2.49 2.48-2.50 
61-90 3.49 3.48-3.51 
91-149 3.11 3.09-3.12 
>150 2.42 2.41-2.42 
Multiple Provider Episode (MPE)3  2.55 2.51-2.58 
1Confidence interval 
2Controlled Substance Prescription 
3MPE: Patients utilizing ≥5 prescribers and 5≥ pharmacies in 12-month period 
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MANUSCRIPT 3 
 
Prevalence and Factors Associated with Multiple Provider Episodes in Texas:  
An Epidemiological Analysis of Prescription Drug Monitoring Program Data 
 
 Abstract 
 
Background:  Prescription drug abuse has reached epidemic levels, leading to dire health 
outcomes and economic implications.  Both patient-level and environmental-level factors 
are believed to contribute to higher rates of prescription drug abuse.  While national 
estimates of abuse have been extensively studied, this phenomenon has not been 
examined in the State of Texas.  The objective of this research was to determine the 
prevalence and factors associated with multiple provider episodes in Texas. 
Methods:  This study was a retrospective, cohort analysis of data obtained from the 
Texas prescription drug monitoring database (PDMP) which was linked with Texas 
county-level census data.  Descriptive statistics and multi-level model regression analysis 
were employed to determine the prevalence of multiple provider episodes (MPE) and 
analyze the association between patient-level, prescription utilization and county-level 
factors with MPEs.  
Results: Opioid prescriptions, especially hydrocodone-combination products (38.64%), 
were the most frequently utilized controlled substance prescriptions (CSPs) dispensed.  
The prevalence of MPEs was 185.16 per 100,000 population.  Among those identified in 
the MPE cohort, 76.98% utilized CSPs >150 days and 11.48% had a daily morphine 
equivalent (MED) ≥100 mg/day.  Residing in metropolitan areas, traveling >100 miles to 
obtain prescriptions, chronic use of CSPs, younger age, and high daily MED were all 
factors significantly associated with an increased risk of MPE. 
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Conclusion: Prescription drug abuse has been identified as a major public health problem 
in Texas. Prescription drug abuse prevention efforts need to be addressed at both the 
patient-level and through legislation regarding public health and policy. 
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Introduction 
 Prescription drug misuse and abuse in the U.S. has reached epidemic levels 
(Centers for Disease Control and Prevention, 2013b; S. E. McCabe et al., 2008).  This 
epidemic has resulted in unprecedented morbidity and mortality and may be indicative of 
the high utilization of prescription opioids in the US.  Reports concerning international 
drug consumption showed that the US accounted for almost all hydrocodone 
consumption (99%) and the vast majority of oxycodone consumption (83%), globally 
(International Narcotics Control Board, 2013).  The Substance Abuse and Mental Health 
Services Administration (SAMHSA) 2013 National Survey on Drug Use and Health 
(NSDUH) indicated that 15.7 million persons aged 12 or older reported using 
pharmaceutical nonmedically within the past year (Substance Abuse and Mental Health 
Services Administration Center for Behavioral Health Statistics and Quality, 2013a).  The 
National Institute on Drug Abuse (NIDA) defines the nonmedical use as using 
prescriptions in a way other than as prescribed (National Institute on Drug Abuse, 
2014d).  Additionally, 4.5 million persons reported nonmedical use of opioids within the 
past month in 2013, an over 75% increase from 2002 (Jones, 2012; Substance Abuse and 
Mental Health Services Administration, 2014a).  One report from NIDA found opioids to 
be present in 50% of cases seen in emergency departments related to nonmedical-use of 
pharmaceuticals (National Institute on Drug Abuse, 2011d).  Drug overdoses were found 
to be the leading cause of injury related deaths in the United States in 2012, 
outnumbering the number of deaths due to motor vehicle accidents (Centers for Disease 
Control and Prevention, 2014d).  The mortality associated specifically with prescription 
drug abuse is estimated at 46 deaths per day, with the majority of cases attributed to 
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prescription opioids (Centers for Disease Control and Prevention, 2014c; LJ Paulozzi et 
al., 2011; Substance Abuse and Mental Health Services Administration, 2014a).  
Moreover, the economic impact of prescription drug abuse is vast, considering that abuse 
of opioids alone results in approximately $53-$72 billion in societal and medical costs 
each year (Birnbaum et al., 2011; Coalition Against Insurance Fraud, 2007; Hansen et al., 
2011).  
 Previous literature has shown that both patient-level factors and environmental 
factors contribute to an increased likelihood of developing prescription drug misuse and 
abuse (Buurma et al., 2008; Fishman, 2010; Han et al., 2012; Jones, 2012; Wilsey et al., 
2010).  Patient-level factors include younger age (e.g., 18-25),(Buurma et al., 2008; 
Fishman, 2010; Han et al., 2012; Peirce et al., 2012; Wilsey et al., 2010) being 
male,(Substance Abuse and Mental Health Services Administration, 2014a; U.S. 
Department of Health and Human Services, 2013) and the number and type of controlled 
substance prescriptions (CSPs) utilized (Fishman, 2010; Hall et al., 2008; Han et al., 
2012; Katz et al., 2010; Kim et al., 2014; Rosenblum et al., 2007; White et al., 2005; 
Wilsey et al., 2010).  Environmental factors, such as a patient’s region or county, are also 
believed to play a role in the propensity for abuse, given that individuals in the same 
geographic region often have comparable access to healthcare resources and share similar 
sociodemographic characteristics (Fishman, 2010; Hall et al., 2008; Han et al., 2012; 
PDMP Center of Excellence, 2012; Simeone et al., 2006).  For example, the increased 
availability of healthcare providers in a region has been highly correlated with an 
elevated propensity for behaviors associated with abuse (e.g., utilizing multiple providers 
to obtain CSPs) (Curtis et al., 2006; Han et al., 2012).  
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 The Centers for Disease Control (CDC) has recommended that prescription drug 
abuse prevention efforts target patients at highest risk in terms of prescription opioid 
dosage and the numbers of CSPs and prescribers utilized (Centers for Disease Control 
and Prevention, 2013b).  This includes patients who obtain CSPs from multiple 
prescribers without the prescriber’s knowledge of the other prescriptions (Centers for 
Disease Control and Prevention National Center for Injury Prevention and Control 
Division of Unintentional Injury Prevention, 2012; McDonald & Carlson, 2013; Sansone 
& Sansone, 2012).  This patient behavior is often referred to as doctor shopping, 
pharmacy shopping, or as having multiple provider episodes (MPEs), which recognizes 
the combination of both definitions.  More importantly, patients identified with a MPE 
often represent a significant contribution to prescription drug diversion rates.  The 
aforementioned high-risk utilization of CSPs is considered aberrant CSP utilization 
behavior.  Aberrant use is defined as using CSPs in a way other than intended by the 
original prescriber (Back et al., 2010; National Institute on Drug Abuse). 
 Contemporary PDMPs are designed to address issues of prescription drug abuse 
and diversion (Astho, 2014).  PDMPs are statewide electronic databases which collect 
designated data on CSPs dispensed within the respective state. One benefit of PDMPs is 
their capability to track patients’ CSP history longitudinally (U.S. Department of Justice 
Drug Enforcement Administration Office of Diversion Control, 2011).  Data collected by 
PDMPs can be utilized as a public health surveillance tool if the appropriate resources are 
designated.  Ideally, PDMPs would be utilized as a public health tool to reduce 
morbidity, mortality and to improve health outcomes regarding pain management 
(Centers for Disease Control and Prevention, 2001).  Using the California PDMP, Wilsey 
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et al. was able to identify the CSPs most frequently associated with MPEs (Wilsey et al., 
2010).  Also in California, Gilson et al. examined the effect of policy changes on opioid 
prescribing behavior following the implementation of the state’s electronic PDMP system 
(AM Gilson et al., 2012).  
 In prior research, physicians’ access of PDMP data was shown to impact their 
clinical decision-making, reduce excessive CSP prescribing, and reduce prescription drug 
abuse and doctor shopping (Haffajee et al., 2015; PDMP Center of Excellence, 2014a; 
Simeone et al., 2006; U.S. General Accounting Office, 2002).  Moreover, studies have 
reported that in an emergency department setting, after reviewing PMDP data, providers 
changed their clinical management plan in 41% of the cases (D Baehren et al., 2010).  A 
survey from Green at al. also found that pharmacists were utilizing PDMP data to screen 
their patients for abuse and doctor shopping (Green et al., 2013). 
 The current extent of prescription drug abuse and overdose deaths in Texas is not 
well known, and is believed to be drastically underestimated (Olsen & Roser, 2015).  
However, Harris County, home to Houston which is the fourth largest city in the US, has 
been identified as one of the nation’s top hotspots for prescription drug abuse (Horswell, 
2010, 2012).  Therefore, this study used MPEs to assess the magnitude of prescription 
drug abuse and the associated factors in Texas.  The objective of this study was to 
examine the prevalence and individual-level and regional-level factors associated with 
patients having an MPE.   
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Methods 
Study Design and Data Source 
 This was a retrospective cohort epidemiological analysis of data from the Texas 
PDMP database.  The Texas PDMP database is operated under the authority of Texas 
Department of Public Safety (DPS) and contains information on all outpatient CSPs 
dispensed from outpatient and community pharmacies in the state.  This study included 
all prescriptions filled from June 1, 2013 to June 1, 2014 (Texas Department of Public 
Safety Regulatory Services Division).  Patients in this database filled at least one CSP 
during the data analysis period. This database consists of 39,904,964 CSPs, obtained by 
10,688,720 patients, written by 113,143 prescribers, and dispensed at 5,155 pharmacies.  
The data was deidentified by the PDMP vendor prior to data acquisition.  After data 
cleaning, removing missing and implausible observations, and restricting the analysis to 
only Texas patients, a total of 38,350,287 CSPs obtained by 10,381,532 patients were 
included in the descriptive statistics and final analysis.  The patient-level data from the 
Texas PDMP was also linked with Texas Census Data to obtain county level data on the 
254 counties in Texas (Texas Association of Counties, 2014; Texas Department of State 
Health Services, 2013a, 2013b; Texas Education Agency, 2014; United States 
Department of Labor, 2013). 
 This study examined two CSP utilization cohorts for descriptive purposes and 
analysis.  The first cohort consisted of all Texas patients utilizing CSPs during the 12-
month study period (n=10,381,532).  The second cohort was comprised of patients with 
at least one MPE during the study period. 
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Dependent Variable 
 The dependent variable employed in this study was presence of MPEs, which was 
defined as utilizing ≥5 prescribers and ≥5 pharmacies within a 12-month period.  Prior 
research by Hall et al. and the Bureau of Justice also similarly operationalized MPE by 
the aforementioned definition (i.e., ≥5 prescribers and ≥5  pharmacies) (Bureau of Justice 
Assistance, 2013; Hall et al., 2008).  However, within the extant literature, there is no 
agreed upon gold standard for defining shopping behavior or MPE (Buurma et al., 2008; 
Cepeda et al., 2014; M. Cepeda, D. Fife, Y. Yuan, et al., 2013; AM Gilson et al., 2012; 
Hall et al., 2008; Katz et al., 2010; Peirce et al., 2012; Substance Abuse and Mental 
Health Services Administration Center for Behavioral Health Statistics and Quality, 
2013b; Wilsey et al., 2010).  Therefore, a sensitivity analysis was conducted based on 
other previously utilized definitions of MPE (e.g., ≥4 doctors and ≥4 prescribers, ≥5 
doctors and/or ≥5 prescribers) to determine the prevalence of MPEs based on the defined 
criteria.   
 
Independent Variables 
 The independent variables in the analysis included both patient-level variables 
and county-level variables, as detailed below.  The patient-level covariates included: 
patient age category; the number of CSPs utilized in the 12-month study period; the 
duration of CSP utilization (total days of use); average daily morphine equivalent dose 
(MED); the distance between the patient’s zip code and CSP prescriber’s zip code; the 
distance between the patient’s zip code and the dispensing pharmacy’s zip code; and the 
distance between the prescriber’s zip code and the dispensing pharmacy’s zip code.   
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County-Level Factors 
 The county-level variables included in the analysis were: county population; race 
(percent nonwhite population); percent uninsured; percent unemployed; high school 
graduation rate; ratio of direct patient care clinicians per 100,000 population; and ratio of 
pharmacists per 100,000 population. 
 
Statistical Analysis 
 Descriptive statistics were conducted on both the main cohort of Texas patients 
utilizing CSPs and also among the MPE cohort.  The association between patient-level, 
prescription utilization and county-level factors and having a MPE were examined using 
multilevel logistic regression modeling.  Multilevel modeling takes into account the 
similarities and correlations of patients clustered within counties (Snijders & Bosker, 
2012).  The PDMP data was also mapped spatially by Texas zip code.  This technic 
allowed for the authors to visually identify the prevalence of MPEs and hot spots for 
utilization of multiple providers across the state.  All statistical analyses were conducted 
using SAS Statistical Software 9.3.  This study and its research activities were approved 
by The Institutional Review Board at the University of Houston. 
 
Results 
 Descriptive statistics of the main cohort and among the MPE cohort are provided 
in Table 3.1.  The prevalence of MPEs based on differently defined criteria (e.g., ≥4 
prescribers and ≥ pharmacies) is provided in Table 3.2.  In general, patients utilizing 
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CSPs displayed conservative behavior in their prescription and healthcare provider 
utilization.  During the 12 months of analysis, patients filled a mean (M±SD) 3.62 ± 5.42 
for CSPs, utilized a M = 1.39 ± 0.88 prescribers and M = 1.19 ± 0.58 pharmacies to 
obtain their CSPs.  However, patients with indicators of aberrant behavior contributed 
significantly to the number of CSPs filled and to healthcare provider utilization.  At least 
one patient was identified with 473 CSPs during the study period; two other patients 
utilized up to 43 different prescribers and filled prescriptions at 39 different pharmacies.   
 This study identified 19,223 patients with a MPE, equivalent to 185.16 MPEs per 
100,000 population.  Almost 24% of all MPEs occurred in Harris County (home to 
Houston), producing a rate of 104.93 per 100,000 population within the county.  The 
most frequently utilized CSPs were opioids (e.g., oxycodone) in both the main cohort 
(38.64%) and the MPE cohort (64.93%). Utilization of a high daily dosage was relatively 
low in the main cohort with only 2.34% of patients utilizing a daily MED ≥100 mg, 
however, 11.48% of patients in the MPE cohort utilized greater than 100 mg daily. 
Additionally, a much larger percentage of patients in the MPE cohort utilized CSPs for a 
longer duration compared to the those without a MPE (>150 days, 76.98% vs 12.49%, 
respectively) and traveled further to obtain prescriptions from prescribers (28.75 miles vs. 
25.59 miles). 
 
Patient-Level Factors Associated with MPE 
 The multilevel model produced a McFaden pseudo-R2 of 0.24, which indicates a 
good model fit based on the assumptions of this model (McFadden, 1979).  As compared 
to patients under the age of 18, patients in the 18-34 years of age category had a 6.35 
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times (adjusted odds ratio [OR] = 6.35 [95% CI = 6.01-6.70]) increased odds of having a 
MPE and patients in the 35 to 44 years of age category had a 5.12 times [95% CI = 4.90-
5.47] increased odds (Table 3.3).  An exponential relationship was also found between 
MPE and increasing number of days with CSPs, with patients taking CSPs for greater 
than five months having a 76.34 times [95% CI = 72.86-80.00] increased odds of having 
an MPE.   
 As compared to patients not utilizing prescription opioids, all categories of daily 
MED were at an increased odds of having an MPE.  However, having a daily MED 
between 20 to 99 mg produced the greatest odds of MPE (20 to 49mg, OR = 16.48 [95% 
CI = 16.48-17.01]; 50 to 99 mg, OR = 14.72, [95% CI = 14.48-14.98]).  Patients traveling 
further than 25 miles from their home to visit a prescriber and pharmacy were also at an 
increased risk of having an MPE.  However, traveling further than 100 miles to receive a 
CSP from a prescriber or to obtain it from a pharmacy had the greatest odds of having 
MPEs (distance to prescriber, OR = 2.02 [95% CI = 1.97-2.06]; distance to pharmacy, 
OR = 1.48 [95% CI = 1.46-1.51]).  
 
County-Level Factors Associated with MPE 
 Among the county-level variables, patients living in a metropolitan area 
(>1,000,000 population) were found to have a 7.30 times [95% CI = 7.06-7.55] increased 
odds of having MPEs, when compared to those in living in rural counties (<15,000 
population).  Counties with higher educational attainment exhibited increased odds of its 
residents having MPEs (>90% graduation rate (OR= 1.60 [95% CI = 1.53-1.67]).  
Counties with higher uninsured patients (>30%) and a higher pharmacy ratio (>100 per 
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100,000 population) were found to have a reduced odds of having MPEs (OR = 0.67 
[95% CI = 0.66-0.69]; OR = 0.74 [95% CI = 0.72-0.77], respectively).  Race distribution 
and unemployment rates within counties were not found to have a statistically significant 
relationship with having MPEs.  The results of the spatial mapping indicate a high 
prevalence of MPEs in the metropolitan areas of Texas, including areas within Houston, 
Dallas, San Antonio and Austin (see Figure 3.1). 
 
Discussion 
 This study is one of the first epidemiological analyses of prescription drug abuse 
(i.e., MPEs) in Texas.  The utilization of PDMP data gives new insight into CSP 
utilization and abuse within the state.  After analyzing the Texas PDMP data in 
conjunction with county census data, the prevalence of CSP utilization and MPEs were 
identified, as well as factors which may put patients at an increased risk for prescription 
drug abuse.  While this study identified 185.16 MPEs per 100,000 population, these 
results may also be conservative due to observations that were deleted due to missing 
values.  In comparison, a study conducted among Washington patients which employed 
the analysis of PDMP data and utilized the same definition for MPE (i.e., ≥5 doctors 
and/or ≥5 prescribers) found that 7.3 per 100,000 population were involved in MPEs 
(PDMP Center of Excellence, 2015).    
 Among the main cohort (all CSP utilization patients) and especially in the MPE 
cohort, opioids, particularly hydrocodone-combination products, were the most 
frequently utilized Scheduled prescriptions.  This finding is consistent with opioid 
prescribing trends across the US (IMS Institute for Healthcare Informatics, 2014).  Also 
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similar to this study, an association was found between higher daily MED and MPEs in 
this analysis (Han et al., 2012).  Han et al (2012) conducted an analysis of California 
PDMP data and also found a strong association between the utilization of as little as >40 
mg of opioids per day and use of new providers.  While utilization of opioids at any dose 
was found to increase a patient’s odds of an MPE, both this study and the study 
conducted by Han et al. have demonstrated a linear relationship between increasing MED 
and odds of MPE.  
 Another alarming finding from this study was the high prevalence of patients 
receiving chronic CSP therapy.  With 12.5% of the main cohort and over 75% of the 
MPE cohort utilizing CSPs for greater than five months, this raises concerns about the 
current culture in which patients rely heavily on CSP therapy, which can increase their 
risks for tolerance and dependence.  Similar to findings reported by NIDA, the results of 
this year-long study also highlight the extensive utilization of opioids in pain 
management over the past decade (Volkow, 2014).   
 The main cohort and the MPE cohort were both comprised of less than 25% of 
individuals under the age of 35; however patients in the 18-34 years of age category had 
the greatest association with having a MPE.  This finding is consistent with previous 
studies which examined factors associated with prescription drug abuse (Buurma et al., 
2008; Fishman, 2010; Han et al., 2012; Peirce et al., 2012; Wilsey et al., 2010).  Also 
consistent with the findings from Cepeda et al., is the association found between patients 
traveling further distances to obtain CSPs from prescribers and pharmacies had an 
increased odds of MPEs (M. Cepeda, D. Fife, Y. Yuan, et al., 2013).  This trend may be 
indicative of doctor shopping patients trying to avoid detection by traveling to prescribers 
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and pharmacies in different locations. Although, this study did not include out of state 
patients traveling to Texas to fill their CSPs in the analysis, these findings further support 
the need for PDMPs not only to be utilized, but to be interconnected with other PDMPs, 
especially in bordering states.  
  As revealed from the results of both the spatial mapping and the multilevel 
logistic model, residing in metropolitan areas (>1,000,000 residents) increased the odds 
of MPEs, which is consistent with findings from Hal et al. (Han et al., 2012).  Identifying 
that metropolitan areas have the greatest proportion of MPEs can assist with the 
allocation of resources for prescription drug abuse prevention efforts by targeting these 
high risk metropolitan areas and communities.  Two noteworthy findings from this study 
were that counties with higher educational attainment have increased odds of MPEs and 
the variable capturing racial distribution and unemployment rates within counties were 
found to be insignificant.  This highlights the need for prescribers and pharmacists to be 
aware that no longer are stereotypical drug abuser profiles the norm, but recognize that 
the problem is now more widespread across diverse populations.  
 Prescription drug abuse has serious public health implications and not identifying 
and addressing these issues could have catastrophic effects.  This issue is heightened to 
an even greater extent given that opioid dependence is believed to a significant predictor 
of future heroin abuse and is one of the factors that have led to the recent increase in 
heroin use (American Society of Addiction Medicine, 2015; Lakey & Lewis, 2014; 
Muhuri et al., 2013).  Previous surveys have found that up to 80% of heroin users have 
also reported engaging in prior abuse of prescription drugs (Lakey & Lewis, 2014).   
Given the magnitude of heroin overdose, prescriber, pharmacist and patient education 
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regarding opioid use and pain management is imperative in order to mitigate the 
prescription drug abuse epidemic.  Opioid dependence remains a serious public health 
issue that should be addressed with patients, but just as important through public policy 
and legislation that focuses on substance treatment. 
 Professional healthcare organizations and healthcare provider educational 
programs need to provide prescribers and pharmacists with more resources and training 
in prescription drug abuse intervention efforts.  Patients in this study were able to receive 
up to 473 CSPs from up to 43 prescribers and fill at 39 different pharmacies, thus it is 
evident that the Texas PDMP is not being utilized to its full potential.  Currently, 
pharmacists in Texas are required to report dispensing information on all CSPs within 
seven days of the fill date to the state PMDP (National Alliance for Model State Drug 
Laws, 2014c).  However, prescribers and pharmacists in Texas are not currently required 
to check the patient’s profile in the PDMP database before dispensing CSPs.  Therefore, 
state legislation should make it mandatory for prescribers and pharmacists to query the 
state's PDMP database to examine patients’ CSP history before issuing prescriptions or 
dispensing CSPs.  Finally, more epidemiological studies addressing issues related to CSP 
use is warranted in Texas.  Local public health authorities can more readily and 
efficiently serve populations through resource allocation, prevention and treatment efforts 
if they understand the prevalence and distribution of MPEs.  One recommendation based 
on the results of this study would be the creation of yearly reports from the state PDMP 
data which are based on the current standards created by the Prescription Behavior 
Surveillance System (PBSS).  This reporting system acts as a early warning and 
surveillance tool to assess trends in CSP prescribing, dispensing practices and indicators 
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of prescription drug abuse (PDMP Center of Excellence, 2015).  Future epidemiological 
studies conducted using PDMP data will help identify health outcomes, prescribing 
behavior, the effectiveness of initiatives and policies, utilization rates and quantification 
of behaviors associated with abuse. 
 
Limitations 
 The results of this study should be interpreted in the context of several limitations.  
One limitation of utilizing PDMP data is the lack of patient clinical and diagnostic 
information.  Therefore, the appropriateness of all CSP use cannot be readily determined.  
Clinical data may verify that a patient has a diagnosis (e.g., cancer) warranting elevated 
CSP use.  When abuse is suspected, prescribers consult the patient’s clinical information 
and pharmacists should follow up with the patient’s prescribers.  Additionally, given the 
lack of a standard definition for MPE, setting a specific threshold of 5 doctors and 5 
pharmacies in 12 months may result in the unintended consequence of a high risk for 
false negatives.  However, this study addressed this issue by expanding the definition of 
doctor shopping to include utilizing both multiple prescribers and multiple pharmacies.  
The statistically significant variables based on these analyses did not differ across 
definitions, nor did their effect sizes differ significantly.  This study may also lack 
generalizability to states other than Texas.  PDMP programs operate under different 
conditions within each specific state and may collect different data.  Not to mention state 
policies influencing the prescribing and availability of CSPs may vary across states.  This 
analysis only included patients residing in Texas; therefore patients traveling to Texas 
from outside the state to obtain prescriptions from multiple providers were not examined.  
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 Despite the limitations cited, this study is one of the first epidemiological analyses 
of CSP utilization in Texas.  To the authors knowledge this is also the first examination 
of the prevalence of MPEs and association between patient-level and county-level factors 
with utilization of multiple providers within the state.  While future research utilizing 
PMDP data containing more extensive patient-level data is needed, this study highlighted 
how aberrant CSP utilization behaviors, such as MPEs, can be identified through patient 
prescription utilization data such as PDMP data. 
 
Conclusion 
 While there are no set standards for identifying prescription drug abuse, PMDP 
data can be utilized to ascertain well-known indicators of abuse and help quantify an 
individual’s propensity for abuse.  The findings of this study suggest that the major issues 
with prescription drug abuse afflicting this country are also very present in Texas.  
Prescription drug abuse prevention efforts need to be focused at the individual level and 
through legislation and public policy due to the far-reaching extent of the problem.  
Recognizing the often dire consequences associated with prescription drug abuse, this 
study calls for policy changes which promote the safe and responsible prescribing of 
CSPs both in Texas and nationwide. 
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Tables and Figures 
Table 3.1. Descriptive Statistics of All Controlled Substance Prescription Utilization in Texas and 
Among a Multiple Provider Episode Cohort 
  All CSP
1 Utilization in Texas 
(10,381,532) 
MPE2 Cohort 
(19,223) 
Variable  Frequency Percent Frequency Percent 
Number of 
Prescriptions 
Accounted For 
 38,350,287 100 492,931 
 
1.28 
 
Age Distribution 
<18 927,144 8.93 89.0 0.46 
18-34 2,248,759 21.66 4,655 24.22 
35-44 1,619,562 15.60 5,041 26.22 
45-64 3,528,745 33.99 8,319 43.28 
65-74 1,139,414 10.98 893 4.65 
≥75 917,908 8.84 226 1.18 
Frequency by 
Class of Medication 
Opioids 14,510,859 38.64 319,854 64.93 
Benzodiazepines 8,229,548 21.92 56,536 11.49 
Sedative 3,421,778 9.11 25,419 5.16 
Stimulants 4,367,227 11.63 20,871 4.24 
Muscle Relaxant 870,440 2.32 18,009 3.66 
Steroids/Hormones 788,834 2.10 1,821 0.37 
Barbiturates 229,949 0.61 1,425 0.29 
Other 5,931,652 13.67 48,996 9.86 
Top CSPs 
Dispensed 
(by drug name, any 
strength) 
 
 
Hydrocodone- 
APAP 13,246,938 34.54 
Hydrocodone -
APAP 193,888 39.33 
Xanax® 
(alprazolam) 3,411,191 9.01 
Xanax® 
(alpraxolam) 36,554 8.62 
Ambien® 
(zolpidem tartrate) 3,058,117 8.08 
Ambien® 
(zolpidem 
tartrate) 
32,646 6.62 
Klonopin® 
(clonazepam) 1,889,166 5.00 
Soma® 
(carisoprodol) 31,788 6.45 
Ativan® 
(lorazepam) 1,385,439 3.67 
Klonopin® 
(clonazepam) 22,833 4.63 
Mixed Ampethamine 
Salts 
(Adderall®) 
1,199,943 3.12 
Mixed 
Ampethamine 
Salts 
(Adderall®) 
14,606 2.96 
Average Daily 
Morphine 
Equivalent 
0 5,163,761 49.74 818 4.26 
1-19mg 1,519,756 14.64 2,092 10.88 
20-49 2,621,524 25.25 10,788 56.13 
50-99 833,655 8.03 3,317 17.26 
≥100 242,484 2.34 2,206 11.48 
Total Days with 
CSP (during 365 
days of analysis) 
1-30 4,849,813 46.72 252 1.31 
31-60 2,904,381 27.98 747 3.89 
61-90 627,818 6.05 911 4.74 
91-149 703,287 6.77 2,516 13.09 
>150 1,296,233 12.49 14,797 76.98 
1Controlled Substance Prescriptions 
2 Multiple Provider Episode (Utilizing ≥5 prescribers and ≥5 pharmacies in 12-months 
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Table 3.2. Prevalence of Multiple Provider Episodes based on Various Definitions 
Cohort Frequency of Patients 
Frequency of CSP1 
Prescriptions Utilized 
Percent of all 
prescriptions in whole 
dataset 
≥3 Prescribers and ≥3 
Pharmacies 
187,667 
(1.81%) 2,898,677 7.72% 
≥4 Prescribers and ≥4 
Pharmacies 
53,643  
(0.50%) 1,131,939 3.01% 
≥5 Prescribers and ≥5 
Pharmacies2 
19,223  
(0.18%) 492,931 1.31% 
≥6 Prescribers and ≥6 
Pharmacies 
8,243 
(0.08%) 246,035 0.65% 
1Controlled Substance Prescriptions 
2Definition used for statistical analysis 
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Table 3.3 Patient and County-Level Factors Associated with  
Multiple Provider Episodes 
Patient-Level Variables 
 Variable Odds Ratio 95% C.I. 
Age category 
(<18 reference) 
18-34 6.35 6.01-6.70 
35-44 5.12 4.90-5.47 
45-64 2.61 2.47-2.75 
65-74 0.91 0.86-0.96 
>75 0.31 0.29-0.33 
Distance Between Patient Zip and 
Prescriber Zip 
(1-25 miles reference) 
26-99 miles 1.64 1.61-1.66 
>=100 2.02 1.97-2.06 
Distance Between Patient Zip and 
Pharmacy Zip 
(1-25 miles reference) 
26-99 miles 1.45 1.43-1.7 
>=100 1.48 1.46-1.51 
Distance Between Prescriber and 
Pharmacy  
(1-25 miles reference) 
26-99 miles 0.70 0.69-0.71 
>=100 0.75 0.74-0.76 
Number of Controlled Substance 
Prescriptions (continuous) 1.024 1.023-1.025 
Daily Morphine Equivalent 
(0 mg reference) 
1-19mg 8.40 8.24-8.54 
20-49mg 16.74 16.48-17.01 
50-99mg 14.72 14.48-14.98 
>100mg 10.14 9.96-10.32 
Total Study Days with CSPs1 
(<30 reference) 
31-60 7.29 6.92-7.68 
61-90 22.21 21.13-23.35 
91-149 39.01 37.20-40.91 
>150 76.34 72.86-80.00 
County-Level Variables 
Population 
(<15,000 reference) 
15,000-99,999 1.68 1.63-1.73 
100,000-1,000,00 3.21 3.11-3.31 
>1,000,000 7.30 7.06-7.55 
Race 
(Percent nonwhite) 
(<10 reference) 
11-19% 0.97 0.96-0.98 
>20% 0.96 0.94-0.97 
Percent Uninsured 
(<20% reference) 
21-29 0.59 0.58-0.59 
>30% 0.67 0.66-0.69 
Ratio of  Direct Patient Care 
Clinicians (per 100,000) 
(<20 reference) 
21-99 0.89 0.86-0.91 
>100 0.98 0.95-1.01 
Percent Unemployed 
(<10% reference) >10% 1.00 0.98-1.02 
High School Graduation Rate 
(<=75 reference) 
76-90% 1.34 1.31-1.43 
>90% 1.60 1.53-1.67 
Pharmacist Ratio 
per 100,000 Population 
(<25 reference) 
26-99 0.76 0.74-0.78 
>100 0.74 0.72-0.77 
1Controlled Substance Prescriptions 	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Figure 3.1. Frequency of Multiple Provider Episodes by Texas Zip Code 
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SUMMARY OF FINDINGS 
 
 
Objective I 
Aberrant CSP1 behavior which can be identifiable through PDMP2 data 
§ Multiple provider episodes (MPEs): individuals who obtain prescriptions for the 
same medications and/or CSPs from multiple prescribers without the prescribers’ 
knowledge of the other prescriptions. 
§ Represent a significant contribution to diversion rates and are responsible for 
a disproportionately large number of CSPs. 
§ Simultaneous and/or overlapping CSPs 
§ Responsible for an excess of overdose deaths, serious adverse events, 
emergency room visits 
§ High daily dosage 
§ Associated with an increased risk for overdose death, emergency room visits 
and likelihood of having mental health problems 
§ Using PDMP data to identify patients with aberrant CSP utilization behaviors can 
be beneficial for both clinical care and for public health surveillance practices. 
1Controlled substance prescription 
2Prescription drug monitoring program data 
 
Objective II 
Prevalence of patients receiving potentially inappropriate overlapping CSPs1 in the State 
of Texas 
§ There were 1,660,015 patients (15.99%) with one of the following inappropriate 
combinations of CSPs: 1) overlapping opioid, muscle relaxant, and 
benzodiazepine prescriptions (Triple Cocktail); 2) overlapping opioid and 
benzodiazepine prescriptions; 3) overlapping opioid, stimulant, and 
benzodiazepine prescriptions; 4) overlapping stimulant and benzodiazepine 
prescriptions; and 5) overlapping opioid prescriptions 
§ 17.23% (n=1,574,572) of all CSP use patients had overlapping opioid 
prescriptions and 90.78% (n=17,450) of patients in the MPE2 cohort 
§ 95.17% of overlapping opioid prescriptions were for 2 short acting opioids 
Factors associated with patients receiving potentially inappropriate overlapping CSPs in 
the State of Texas 
§ Age categories between >18 years of age 
§ Traveling >25 miles to obtain prescriptions for CSPs 
§ Obtaining more than one CSP 
§ Daily MED3 ≥1mg/day 
§ Utilizing CSPs >30 days 
§ Having MPEs 
1Controlled substance prescription 
2Multiple provider episode 
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Objective III 
 
Identify the current state and burden of CSP1 use and abuse in Texas 
§ 38.64% of all CSPs dispensed were for opioids 
§ Hydrocodone combination products were the most frequently prescribed CSP 
(34.54%) 
Prevalence and individual-level and regional-level factors associated with patients having 
an MPE1 in the State of Texas 
§ 19,223 patients with a MPE (185.16 MPEs per 100,000 population) 
§ Individual-level variables that are significantly associated with an increased risk 
for MPE: 
§ age categories between 18-64 years of age 
§ traveling >25 miles to obtain prescriptions for CSPs 
§ traveling >25 to fill CSPs at a pharmacy 
§ Obtaining more than one CSP 
§ Daily MED3 ≥1mg/day 
§ Utilizing CSPs >30 days 
§ County-level variables that are significantly associated with patients having an 
MPE1 in the State of Texas: 
§ Residing in county with population >15,000 
§ County high school graduation rate >76% 
§ MPEs were highly centralized in Texas metropolitan areas (e.g., Houston, Dallas, 
San Antonio) 
1Controlled substance prescription 
2Multiple provider episode  
3Morphine equivalent dose 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	   117	  
 
CONCLUSIONS 
 
 
 This research study was a foundation for establishing the current state of CSP use 
and abuse in the State of Texas.  A high prevalence of aberrant CSP utilization behaviors 
was found among Texas patients, such as the use of multiple providers to obtain CSPs, 
overlapping prescriptions for CSPs, and utilization of a high daily morphine equivalent 
dose (MED).  However, utilizing both logistic regression and multilevel modeling this 
study also identified both patient-level and regional-level factors significantly associated 
with these aberrant behaviors.  This research will also allow for patients in these high-risk 
categories to be more readily identifiable using a combination of individual-level 
variables, CSP utilization behaviors and county-level characteristics.  The utilization of 
PDMP data in this study also demonstrated the utility of this relatively underutilized type 
of data for both clinical and epidemiological purposes.  The findings of this research 
support the future utilization of the Texas PDMP not only as a clinical tool for both 
prescribers and pharmacists, but for future research purposes, particularly those which 
address the prescription drug abuse epidemic in Texas 
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